| 1 |
Schoellhammer CM, Lauwers GY, Goettel JA, Oberli MA, Cleveland C, Park JY, Minahan D, Chen Y, Anderson DG, Jaklenec A, Snapper SB, Langer R, Traverso G. Ultrasound-Mediated Delivery of RNA to Colonic Mucosa of Live Mice. Gastroenterology 2017;152:1151-60. [PMID: 28088460 DOI: 10.1053/j.gastro.2017.01.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 2 |
Gampierakis IA, Koutmani Y, Semitekolou M, Morianos I, Polissidis A, Katsouda A, Charalampopoulos I, Xanthou G, Gravanis A, Karalis KP. Hippocampal neural stem cells and microglia response to experimental inflammatory bowel disease (IBD). Mol Psychiatry 2021;26:1248-63. [PMID: 31969694 DOI: 10.1038/s41380-020-0651-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 3 |
Steinmann S, Scheibe K, Erlenbach-Wuensch K, Neufert C, Schneider-Stock R. Death-associated protein kinase: A molecule with functional antagonistic duality and a potential role in inflammatory bowel disease (Review). Int J Oncol 2015;47:5-15. [PMID: 25963636 DOI: 10.3892/ijo.2015.2998] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 4 |
Bonovas S, Nikolopoulos GK, Lytras T, Fiorino G, Peyrin-Biroulet L, Danese S. Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis. Br J Clin Pharmacol 2018;84:239-51. [PMID: 29057539 DOI: 10.1111/bcp.13456] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 5 |
Dammann K, Khare V, Gasche C. Tracing PAKs from GI inflammation to cancer. Gut 2014;63:1173-84. [PMID: 24811999 DOI: 10.1136/gutjnl-2014-306768] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 6 |
Ma Y, Gao W, Zhang Y, Yang M, Yan X, Zhang Y, Li G, Liu C, Xu C, Zhang M. Biomimetic MOF Nanoparticles Delivery of C-Dot Nanozyme and CRISPR/Cas9 System for Site-Specific Treatment of Ulcerative Colitis. ACS Appl Mater Interfaces 2022;14:6358-69. [PMID: 35099925 DOI: 10.1021/acsami.1c21700] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Zhang M, Liu Y, Chen YG. Generation of 3D human gastrointestinal organoids: principle and applications. Cell Regen 2020;9:6. [PMID: 32588198 DOI: 10.1186/s13619-020-00040-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 8 |
Motawea MH, Abd Elmaksoud HA, Elharrif MG, Desoky AAE, Ibrahimi A. Evaluation of Anti-inflammatory and Antioxidant Profile of Oleuropein in Experimentally Induced Ulcerative Colitis. Int J Mol Cell Med 2020;9:224-33. [PMID: 33274185 DOI: 10.22088/IJMCM.BUMS.9.3.224] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
|
| 9 |
Godskesen LE, Lassen TR, Jespersen NR, Siersbæk M, Yan Y, Nielsen MM, Tjønnfjord SK, Grøntved L, Madsen G, Kjems J, Bøtker HE, Schmidt MR, Krag A, Kjeldsen J. Remote ischemic conditioning in active ulcerative colitis: An explorative randomized clinical trial. Sci Rep 2020;10:9537. [PMID: 32533085 DOI: 10.1038/s41598-020-65692-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 10 |
Matsuoka K, Watanabe M, Ohmori T, Nakajima K, Ishida T, Ishiguro Y, Kanke K, Kobayashi K, Hirai F, Watanabe K, Mizusawa H, Kishida S, Miura Y, Ohta A, Kajioka T, Hibi T, Motoya S, Maemoto A, Fujiya M, Ashida T, Goto M, Matsumoto T, Suzuki Y, Hamahata Y, Nakagawa T, Kato N, Kato J, Endo Y, Suzuki R, Matsuda K, Ohmiya N, Katsushima S, Hosomi S, Tarumi K, Watanabe C, Saito M, Yokoyama Y, Inaba T, Sakata Y, Hongo H, Shibuya T, Kawakami K, Kakuta Y, Irisawa A, Yoshimura N, Fukuda K, Shirai T, Ichikawa H, Nagata J, Suzuki T, Yokoyama K, Tomidokoro T, Kojima Y, Yamada M, Yamamoto H, Yamamoto T, Horiki N, Obata H, Inoue S, Tanaka S, Toyokawa T, Kunihiro M, Hisabe T, Ogata S, Takeshima F, Matsushima K, Matsuhashi N, Sakuraba H, Iwabuchi M, Tsuchiya A, Uchiyama K, Kanai T, Nakamura M, Yokoyama T, Hida N, Mitsuyama K, Osada T, Hiraoka S, Tsuzuki T, Masuo T, Hokari R, Kobayashi T, Saruta M, Araki M, Araki H, Shimizu M, Kikuchi M, Nishikawa T, Takedatsu H, Aoyagi K, Ochiai T, Toda N, Mizokami Y, Nagahori M, Matsueda K, Kino H, Kanamori A, Suzuki T, Sakurai T, Kudo M, Kitano A, Hisamatsu T, Kumagai S, Ninomiya T, Mori K, Yoshida S, Goto M. AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Gastroenterology & Hepatology 2022;7:648-57. [DOI: 10.1016/s2468-1253(22)00022-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 11 |
Weigmann B, Neurath MF. Th9 cells in inflammatory bowel diseases. Semin Immunopathol. 2017;39:89-95. [PMID: 27837255 DOI: 10.1007/s00281-016-0603-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 12 |
Espaillat MP, Snider AJ, Qiu Z, Channer B, Coant N, Schuchman EH, Kew RR, Sheridan BS, Hannun YA, Obeid LM. Loss of acid ceramidase in myeloid cells suppresses intestinal neutrophil recruitment. FASEB J 2018;32:2339-53. [PMID: 29259036 DOI: 10.1096/fj.201700585R] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 13 |
Takahashi S, Yoshimura T, Ohkura T, Fujisawa M, Fushimi S, Ito T, Itakura J, Hiraoka S, Okada H, Yamamoto K, Matsukawa A. A Novel Role of Spred2 in the Colonic Epithelial Cell Homeostasis and Inflammation. Sci Rep 2016;6:37531. [PMID: 27869219 DOI: 10.1038/srep37531] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 14 |
Ribaldone DG, Dileo I, Pellicano R, Resegotti A, Fagoonee S, Vernero M, Saracco G, Astegiano M. Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy. Ir J Med Sci 2018;187:385-92. [PMID: 28756540 DOI: 10.1007/s11845-017-1666-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 15 |
Schieffer KM, Williams ED, Yochum GS, Koltun WA. Review article: the pathogenesis of pouchitis. Aliment Pharmacol Ther 2016;44:817-35. [PMID: 27554912 DOI: 10.1111/apt.13780] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 16 |
Kondo S, Araki T, Toiyama Y, Tanaka K, Kawamura M, Okugawa Y, Okita Y, Saigusa S, Inoue Y, Uchida K, Mohri Y, Kusunoki M. Downregulation of trefoil factor-3 expression in the rectum is associated with the development of ulcerative colitis-associated cancer. Oncol Lett. 2018;16:3658-3664. [PMID: 30127975 DOI: 10.3892/ol.2018.9120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 17 |
Wakai M, Hayashi R, Tanaka S, Naito T, Kumada J, Nomura M, Takigawa H, Oka S, Ueno Y, Ito M, Chayama K. Serum amyloid A is a better predictive biomarker of mucosal healing than C-reactive protein in ulcerative colitis in clinical remission. BMC Gastroenterol. 2020;20:85. [PMID: 32245401 DOI: 10.1186/s12876-020-01229-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 18 |
Okamura M, Yoh K, Ojima M, Morito N, Takahashi S. Overexpression of GATA-3 in T cells accelerates dextran sulfate sodium-induced colitis. Exp Anim 2014;63:133-40. [PMID: 24770638 DOI: 10.1538/expanim.63.133] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 19 |
Bonovas S, Pansieri C, Piovani D, Macaluso FS, Orlando A, Festa S, Papi C, Pugliese D, Armuzzi A. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD technical review based on the GRADE methodology. Dig Liver Dis 2022:S1590-8658(22)00134-7. [PMID: 35183439 DOI: 10.1016/j.dld.2022.01.123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Haring E, Zeiser R, Apostolova P. Interfering With Inflammation: Heterogeneous Effects of Interferons in Graft-Versus-Host Disease of the Gastrointestinal Tract and Inflammatory Bowel Disease. Front Immunol 2021;12:705342. [PMID: 34249014 DOI: 10.3389/fimmu.2021.705342] [Reference Citation Analysis]
|
| 21 |
Qazi T, Amaratunga T, Barnes EL, Fischer M, Kassam Z, Allegretti JR. The risk of inflammatory bowel disease flares after fecal microbiota transplantation: Systematic review and meta-analysis. Gut Microbes. 2017;8:574-588. [PMID: 28723262 DOI: 10.1080/19490976.2017.1353848] [Cited by in Crossref: 75] [Cited by in F6Publishing: 66] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 22 |
Maria-ferreira D, Dallazen JL, Corso CR, Nascimento AM, Cipriani TR, da Silva Watanabe P, de Mello Gonçales Sant'ana D, Baggio CH, de Paula Werner MF. Rhamnogalacturonan polysaccharide inhibits inflammation and oxidative stress and alleviates visceral pain. Journal of Functional Foods 2021;82:104483. [DOI: 10.1016/j.jff.2021.104483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 23 |
Matsuoka K, Uemura Y, Kanai T, Kunisaki R, Suzuki Y, Yokoyama K, Yoshimura N, Hibi T. Efficacy of Bifidobacterium breve Fermented Milk in Maintaining Remission of Ulcerative Colitis. Dig Dis Sci. 2018;63:1910-1919. [PMID: 29450747 DOI: 10.1007/s10620-018-4946-2] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 10.8] [Reference Citation Analysis]
|
| 24 |
Mehta P, Furuta GT. Eosinophils in Gastrointestinal Disorders: Eosinophilic Gastrointestinal Diseases, Celiac Disease, Inflammatory Bowel Diseases, and Parasitic Infections. Immunol Allergy Clin North Am 2015;35:413-37. [PMID: 26209893 DOI: 10.1016/j.iac.2015.04.003] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 25 |
Aoyama Y, Inaba T, Takahashi S, Yasuhara H, Hiraoka S, Morimoto T, Colvin HS, Wato M, Ando M, Nakamura S, Mizobuchi K, Okada H. Anti-proteinase 3 antineutrophil cytoplasmic antibody reflects disease activity and predicts the response to steroid therapy in ulcerative colitis. BMC Gastroenterol 2021;21:325. [PMID: 34425765 DOI: 10.1186/s12876-021-01903-5] [Reference Citation Analysis]
|
| 26 |
Wang Z, Li S, Cao Y, Tian X, Zeng R, Liao DF, Cao D. Oxidative Stress and Carbonyl Lesions in Ulcerative Colitis and Associated Colorectal Cancer. Oxid Med Cell Longev 2016;2016:9875298. [PMID: 26823956 DOI: 10.1155/2016/9875298] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 7.1] [Reference Citation Analysis]
|
| 27 |
Smillie CS, Biton M, Ordovas-Montanes J, Sullivan KM, Burgin G, Graham DB, Herbst RH, Rogel N, Slyper M, Waldman J, Sud M, Andrews E, Velonias G, Haber AL, Jagadeesh K, Vickovic S, Yao J, Stevens C, Dionne D, Nguyen LT, Villani AC, Hofree M, Creasey EA, Huang H, Rozenblatt-Rosen O, Garber JJ, Khalili H, Desch AN, Daly MJ, Ananthakrishnan AN, Shalek AK, Xavier RJ, Regev A. Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis. Cell 2019;178:714-730.e22. [PMID: 31348891 DOI: 10.1016/j.cell.2019.06.029] [Cited by in Crossref: 268] [Cited by in F6Publishing: 215] [Article Influence: 134.0] [Reference Citation Analysis]
|
| 28 |
Cozzi D, Moroni C, Addeo G, Danti G, Lanzetta MM, Cavigli E, Falchini M, Marra F, Piccolo CL, Brunese L, Miele V. Radiological Patterns of Lung Involvement in Inflammatory Bowel Disease. Gastroenterol Res Pract 2018;2018:5697846. [PMID: 30158965 DOI: 10.1155/2018/5697846] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 29 |
Johansson ME, Gustafsson JK, Holmén-Larsson J, Jabbar KS, Xia L, Xu H, Ghishan FK, Carvalho FA, Gewirtz AT, Sjövall H, Hansson GC. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut 2014;63:281-91. [PMID: 23426893 DOI: 10.1136/gutjnl-2012-303207] [Cited by in Crossref: 509] [Cited by in F6Publishing: 485] [Article Influence: 63.6] [Reference Citation Analysis]
|
| 30 |
Sun F, Liang W, Tang K, Hong M, Qian J. Profiling the lncRNA-miRNA-mRNA ceRNA network to reveal potential crosstalk between inflammatory bowel disease and colorectal cancer. PeerJ 2019;7:e7451. [PMID: 31523496 DOI: 10.7717/peerj.7451] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 31 |
Sumi T, Yamada G, Yorozuya T, Tanaka Y, Tanaka Y, Sakuma Y, Takahashi H. Sarcoidosis development during ulcerative colitis remission in a patient with a susceptible human leukocyte antigen serotype. Sarcoidosis Vasc Diffuse Lung Dis 2021;38:e2021010. [PMID: 33867794 DOI: 10.36141/svdld.v38i1.6722] [Reference Citation Analysis]
|
| 32 |
Gu Z, Duan M, Sun Y, Leng T, Xu T, Gu Y, Gu Z, Lin Z, Yang L, Ji M. Effects of Vitamin D3 on Intestinal Flora in a Mouse Model of Inflammatory Bowel Disease Treated with Rifaximin. Med Sci Monit 2020;26:e925068. [PMID: 33177483 DOI: 10.12659/MSM.925068] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 33 |
Schoellhammer CM, Traverso G. Low-frequency ultrasound for drug delivery in the gastrointestinal tract. Expert Opin Drug Deliv 2016;13:1045-8. [PMID: 27049815 DOI: 10.1517/17425247.2016.1171841] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 34 |
Gane JM, Stockley RA, Sapey E. TNF-α Autocrine Feedback Loops in Human Monocytes: The Pro- and Anti-Inflammatory Roles of the TNF-α Receptors Support the Concept of Selective TNFR1 Blockade In Vivo. J Immunol Res 2016;2016:1079851. [PMID: 27747245 DOI: 10.1155/2016/1079851] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 35 |
Li T, Hui H, Hu C, Ma H, Yang X, Tian J. Multiscale imaging of colitis in mice using confocal laser endomicroscopy, light-sheet fluorescence microscopy, and magnetic resonance imaging. J Biomed Opt 2019;24:1-8. [PMID: 30701723 DOI: 10.1117/1.JBO.24.1.016003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 36 |
McLean MH, Neurath MF, Durum SK. Targeting interleukins for the treatment of inflammatory bowel disease-what lies beyond anti-TNF therapy? Inflamm Bowel Dis. 2014;20:389-397. [PMID: 24356385 DOI: 10.1097/01.mib.0000437616.37000.41] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 37 |
Sartini A, Bianchini M, Schepis F, Marzi L, De Maria N, Villa E. Complete resolution of non-necrotizing lung granuloma and pyoderma gangrenosum after restorative proctocolectomy in a woman with severe ulcerative colitis and cytomegalovirus infection. Clin Case Rep 2016;4:195-202. [PMID: 26862424 DOI: 10.1002/ccr3.464] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 38 |
Nanda K, Moss AC. Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine. Clin Pharmacol. 2012;4:41-50. [PMID: 22888278 DOI: 10.2147/CPAA.S26556] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 39 |
Oshi MA, Lee J, Naeem M, Hasan N, Kim J, Kim HJ, Lee EH, Jung Y, Yoo J. Curcumin Nanocrystal/pH-Responsive Polyelectrolyte Multilayer Core–Shell Nanoparticles for Inflammation-Targeted Alleviation of Ulcerative Colitis. Biomacromolecules 2020;21:3571-81. [DOI: 10.1021/acs.biomac.0c00589] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 40 |
Mizuno S, Ono K, Mikami Y, Naganuma M, Fukuda T, Minami K, Masaoka T, Terada S, Yoshida T, Saigusa K, Hirahara N, Miyata H, Suda W, Hattori M, Kanai T. 5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis. Intest Res 2020;18:69-78. [PMID: 32013315 DOI: 10.5217/ir.2019.00084] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 41 |
Sánchez A, Calpena AC, Clares B. Evaluating the Oxidative Stress in Inflammation: Role of Melatonin. Int J Mol Sci 2015;16:16981-7004. [PMID: 26225957 DOI: 10.3390/ijms160816981] [Cited by in Crossref: 81] [Cited by in F6Publishing: 75] [Article Influence: 11.6] [Reference Citation Analysis]
|
| 42 |
Himmel ME, Yao Y, Orban PC, Steiner TS, Levings MK. Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers. Immunology. 2012;136:115-122. [PMID: 22348589 DOI: 10.1111/j.1365-2567.2012.03572.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 74] [Article Influence: 7.9] [Reference Citation Analysis]
|
| 43 |
Nielsen OH. New strategies for treatment of inflammatory bowel disease. Front Med (Lausanne). 2014;1:3. [PMID: 25685754 DOI: 10.3389/fmed.2014.00003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 44 |
Tan X, Li C, Yang R, Zhao S, Li F, Li X, Chen L, Wan X, Liu X, Yang T, Tong X, Xu T, Cui R, Jiang H, Zhang S, Liu H, Zheng M. Discovery of Pyrazolo[3,4-d]pyridazinone Derivatives as Selective DDR1 Inhibitors via Deep Learning Based Design, Synthesis, and Biological Evaluation. J Med Chem 2021. [PMID: 34821145 DOI: 10.1021/acs.jmedchem.1c01205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 45 |
Simčič S, Berlec A, Stopinšek S, Štrukelj B, Orel R. Engineered and wild-type L. lactis promote anti-inflammatory cytokine signalling in inflammatory bowel disease patient's mucosa. World J Microbiol Biotechnol 2019;35:45. [PMID: 30810891 DOI: 10.1007/s11274-019-2615-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 46 |
Couvineau A, Voisin T, Nicole P, Gratio V, Blais A. Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions. World J Gastroenterol 2021; 27(44): 7582-7596 [PMID: 34908800 DOI: 10.3748/wjg.v27.i44.7582] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 47 |
Parente JML, Coy CSR, Campelo V, Parente MPPD, Costa LA, Silva RMD, Stephan C, Zeitune JMR. Inflammatory bowel disease in an underdeveloped region of Northeastern Brazil. World J Gastroenterol 2015; 21(4): 1197-1206 [PMID: 25632193 DOI: 10.3748/wjg.v21.i4.1197] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 44] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 48 |
Esmat S, El Nady M, Elfekki M, Elsherif Y, Naga M. Epidemiological and clinical characteristics of inflammatory bowel diseases in Cairo, Egypt. World J Gastroenterol 2014; 20(3): 814-821 [PMID: 24574754 DOI: 10.3748/wjg.v20.i3.814] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 49 |
Thelen TD, Green RM, Ziegler SF. Acute blockade of IL-25 in a colitis associated colon cancer model leads to increased tumor burden. Sci Rep 2016;6:25643. [PMID: 27165713 DOI: 10.1038/srep25643] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 50 |
Wei J, Wei C, Wang M, Qiu X, Li Y, Yuan Y, Jin C, Leng L, Wang J, Yang X, He F. The GTPase-activating protein GIT2 protects against colitis by negatively regulating Toll-like receptor signaling. Proc Natl Acad Sci U S A 2014;111:8883-8. [PMID: 24879442 DOI: 10.1073/pnas.1309218111] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 51 |
Johansson ME, Hansson GC. Mucus and the goblet cell. Dig Dis. 2013;31:305-309. [PMID: 24246979 DOI: 10.1159/000354683] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 7.6] [Reference Citation Analysis]
|
| 52 |
Kwong EK, Zhou H. Sphingosine-1-phosphate signaling and the gut-liver axis in liver diseases. Liver Res 2019;3:19-24. [PMID: 31360579 DOI: 10.1016/j.livres.2019.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 53 |
Martin Mena A, Langlois A, Speca S, Schneider L, Desreumaux P, Dubuquoy L, Bertin B. The Expression of the Short Isoform of Thymic Stromal Lymphopoietin in the Colon Is Regulated by the Nuclear Receptor Peroxisome Proliferator Activated Receptor-Gamma and Is Impaired during Ulcerative Colitis. Front Immunol 2017;8:1052. [PMID: 28928735 DOI: 10.3389/fimmu.2017.01052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 54 |
Ge YF, Guan X, Jiang XJ. Clinical significance of Helicobacter pylori in the grouth of ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2018; 26(17): 1071-1076 [DOI: 10.11569/wcjd.v26.i17.1071] [Reference Citation Analysis]
|
| 55 |
Schoellhammer CM, Schroeder A, Maa R, Lauwers GY, Swiston A, Zervas M, Barman R, DiCiccio AM, Brugge WR, Anderson DG, Blankschtein D, Langer R, Traverso G. Ultrasound-mediated gastrointestinal drug delivery. Sci Transl Med 2015;7:310ra168. [PMID: 26491078 DOI: 10.1126/scitranslmed.aaa5937] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 56 |
Villumsen M, Schelde AB, Jimenez-Solem E, Jess T, Allin KH. GLP-1 based therapies and disease course of inflammatory bowel disease. EClinicalMedicine 2021;37:100979. [PMID: 34386751 DOI: 10.1016/j.eclinm.2021.100979] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 57 |
Silva Rischiteli AB, Neto NIP, Gascho K, Carnier M, de Miranda DA, Silva FP, Boldarine VT, Seelaender M, Ribeiro EB, Oyama LM, Oller do Nascimento CM. A diet including xanthan gum triggers a pro-inflammatory response in Wistar rats inoculated with Walker 256 cells. PLoS One 2019;14:e0218567. [PMID: 31211796 DOI: 10.1371/journal.pone.0218567] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 58 |
Sun J, Zhang H, Wang C, Yang M, Chang S, Geng Y, Yang H, Zhuang Z, Wang X, Xie L, Huang B, Zhao N, Zhou W, Cheng X, Cai B, Wu Q, Yu SG. Regulating the Balance of Th17/Treg via Electroacupuncture and Moxibustion: An Ulcerative Colitis Mice Model Based Study. Evid Based Complement Alternat Med 2017;2017:7296353. [PMID: 29391874 DOI: 10.1155/2017/7296353] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 59 |
Manivannan A, Lee ES, Han K, Lee HE, Kim DS. Versatile Nutraceutical Potentials of Watermelon-A Modest Fruit Loaded with Pharmaceutically Valuable Phytochemicals. Molecules 2020;25:E5258. [PMID: 33187365 DOI: 10.3390/molecules25225258] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 60 |
Mukaida N, Sasaki S. Fibroblasts, an inconspicuous but essential player in colon cancer development and progression. World J Gastroenterol 2016; 22(23): 5301-5316 [PMID: 27340347 DOI: 10.3748/wjg.v22.i23.5301] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 34] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 61 |
Zhong Y, Xiao Q, Li S, Chen L, Long J, Fang W, Yu F, Huang J, Zhao H, Liu D. Bupi Yichang Pill alleviates dextran sulfate sodium-induced ulcerative colitis in mice by regulating the homeostasis of follicular helper T cells. Phytomedicine 2022;100:154091. [PMID: 35395566 DOI: 10.1016/j.phymed.2022.154091] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 62 |
Gerlach K, Hwang Y, Nikolaev A, Atreya R, Dornhoff H, Steiner S, Lehr HA, Wirtz S, Vieth M, Waisman A. TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat Immunol. 2014;15:676-686. [PMID: 24908389 DOI: 10.1038/ni.2920] [Cited by in Crossref: 227] [Cited by in F6Publishing: 215] [Article Influence: 28.4] [Reference Citation Analysis]
|
| 63 |
Pedersen J, Coskun M, Soendergaard C, Salem M, Nielsen OH. Inflammatory pathways of importance for management of inflammatory bowel disease. World J Gastroenterol 2014; 20(1): 64-77 [PMID: 24415859 DOI: 10.3748/wjg.v20.i1.64] [Cited by in CrossRef: 92] [Cited by in F6Publishing: 89] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 64 |
Zhang M, Wang XM, Zhai JS, Zhu CH, Sun HJ, Ji YJ, Li N. Effects of inhibition of interleukin-17F pathway in mice with experimental ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2014; 22(34): 5304-5309 [DOI: 10.11569/wcjd.v22.i34.5304] [Reference Citation Analysis]
|
| 65 |
Kim JY, Zaghiyan K, Lightner A, Fleshner P. Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study.BMC Surg. 2020;20:46. [PMID: 32138717 DOI: 10.1186/s12893-020-00698-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 66 |
van der Post S, Jabbar KS, Birchenough G, Arike L, Akhtar N, Sjovall H, Johansson MEV, Hansson GC. Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis. Gut 2019;68:2142-51. [PMID: 30914450 DOI: 10.1136/gutjnl-2018-317571] [Cited by in Crossref: 129] [Cited by in F6Publishing: 101] [Article Influence: 43.0] [Reference Citation Analysis]
|
| 67 |
Tamburini B, La Manna MP, La Barbera L, Mohammadnezhad L, Badami GD, Shekarkar Azgomi M, Dieli F, Caccamo N. Immunity and Nutrition: The Right Balance in Inflammatory Bowel Disease. Cells 2022;11:455. [DOI: 10.3390/cells11030455] [Reference Citation Analysis]
|
| 68 |
Langhorst J, Frede A, Knott M, Pastille E, Buer J, Dobos GJ, Westendorf AM. Distinct Kinetics in the Frequency of Peripheral CD4+ T Cells in Patients with Ulcerative Colitis Experiencing a Flare during Treatment with Mesalazine or with a Herbal Preparation of Myrrh, Chamomile, and Coffee Charcoal. PLoS One. 2014;9:e104257. [PMID: 25144293 DOI: 10.1371/journal.pone.0104257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 69 |
Zhang Z, Wu X, Cao S, Cromie M, Shen Y, Feng Y, Yang H, Li L. Chlorogenic Acid Ameliorates Experimental Colitis by Promoting Growth of Akkermansia in Mice. Nutrients 2017;9:E677. [PMID: 28661454 DOI: 10.3390/nu9070677] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 9.6] [Reference Citation Analysis]
|
| 70 |
Atreya R, Bloom S, Scaldaferri F, Gerardi V, Admyre C, Karlsson Å, Knittel T, Kowalski J, Lukas M, Löfberg R, Nancey S, Petryka R, Rydzewska G, Schnabel R, Seidler U, Neurath MF, Hawkey C. Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis. J Crohns Colitis 2016;10:1294-302. [PMID: 27208386 DOI: 10.1093/ecco-jcc/jjw103] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 71 |
Li P, Chen K, Mao Z, Luo Y, Xue Y, Zhang Y, Wang X, Zhang L, Gu S, Dou D. Association between Inflammatory Bowel Disease and Pancreatitis: A PRISMA-Compliant Systematic Review. Gastroenterol Res Pract 2020;2020:7305241. [PMID: 32831829 DOI: 10.1155/2020/7305241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 72 |
Löwenberg M, de Boer NKh, Hoentjen F. Golimumab for the treatment of ulcerative colitis. Clin Exp Gastroenterol 2014;7:53-9. [PMID: 24648749 DOI: 10.2147/CEG.S48741] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 73 |
Rogers KV, Martin SW, Bhattacharya I, Singh RSP, Nayak S. A Dynamic Quantitative Systems Pharmacology Model of Inflammatory Bowel Disease: Part 1 - Model Framework. Clin Transl Sci 2021;14:239-48. [PMID: 32822108 DOI: 10.1111/cts.12849] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 74 |
Tripathi K, Feuerstein JD. New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance. Drugs Context 2019;8:212572. [PMID: 31065290 DOI: 10.7573/dic.212572] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 75 |
Cleynen I, Linsen L, Verstockt S, Verstockt B, Ballet V, Vandeput E, Van Assche G, Ferrante M, Van Landuyt K, Vermeire S, Ectors N. Inflammatory Bowel Disease (IBD)-A Textbook Case for Multi-Centric Banking of Human Biological Materials. Front Med (Lausanne) 2019;6:230. [PMID: 31681784 DOI: 10.3389/fmed.2019.00230] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 76 |
Toiyama Y, Okugawa Y, Tanaka K, Araki T, Uchida K, Hishida A, Uchino M, Ikeuchi H, Hirota S, Kusunoki M, Boland CR, Goel A. A Panel of Methylated MicroRNA Biomarkers for Identifying High-Risk Patients With Ulcerative Colitis-Associated Colorectal Cancer. Gastroenterology 2017;153:1634-1646.e8. [PMID: 28847750 DOI: 10.1053/j.gastro.2017.08.037] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 77 |
Zhu J, Wang Z, Chen F, Liu C. Identification of genes and functional coexpression modules closely related to ulcerative colitis by gene datasets analysis. PeerJ 2019;7:e8061. [PMID: 31741804 DOI: 10.7717/peerj.8061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 78 |
Rowan C, Hirten R. The future of telemedicine and wearable technology in IBD. Curr Opin Gastroenterol 2022;38:373-81. [PMID: 35762696 DOI: 10.1097/MOG.0000000000000845] [Reference Citation Analysis]
|
| 79 |
Novacek G, Gröchenig HP, Haas T, Wenzl H, Steiner P, Koch R, Feichtenschlager T, Eckhardt G, Mayer A, Kirchgatterer A, Ludwiczek O, Platzer R, Papay P, Gartner J, Fuchssteiner H, Miehsler W, Peters PG, Reicht G, Vogelsang H, Dejaco C, Waldhör T; Austrian IBD Study Group (ATISG). Diagnostic delay in patients with inflammatory bowel disease in Austria. Wien Klin Wochenschr 2019;131:104-12. [PMID: 30715607 DOI: 10.1007/s00508-019-1451-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 80 |
Manchanda S, Rizvi QUA, Singh R. Role of endoscopy in the surveillance and management of colorectal neoplasia in inflammatory bowel disease. World J Clin Cases 2019; 7(1): 1-9 [PMID: 30637247 DOI: 10.12998/wjcc.v7.i1.1] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 81 |
Bonovas S, Nikolopoulos GK, Piovani D, González-Lorenzo M, Pantavou K, Lytras T, Peyrin-Biroulet L, Danese S. Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis. Br J Clin Pharmacol 2019;85:2244-54. [PMID: 31269287 DOI: 10.1111/bcp.14051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 82 |
Yarani R, Mirza AH, Kaur S, Pociot F. The emerging role of lncRNAs in inflammatory bowel disease. Exp Mol Med 2018;50:1-14. [PMID: 30523244 DOI: 10.1038/s12276-018-0188-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 83 |
Thurner L, Stöger E, Fadle N, Klemm P, Regitz E, Kemele M, Bette B, Held G, Dauer M, Lammert F, Preuss KD, Zimmer V, Pfreundschuh M. Proinflammatory progranulin antibodies in inflammatory bowel diseases. Dig Dis Sci 2014;59:1733-42. [PMID: 24591016 DOI: 10.1007/s10620-014-3089-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 84 |
Roix J, Saha S. TNF-α blockade is ineffective in animal models of established polycystic kidney disease. BMC Nephrol 2013;14:233. [PMID: 24160989 DOI: 10.1186/1471-2369-14-233] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 85 |
Neurath MF. Arzneimitteltherapie in der Gastroenterologie: Molekulare Grundlagen der CED. Drug Res (Stuttg) 2021;71:S15. [PMID: 34788880 DOI: 10.1055/a-1606-5844] [Reference Citation Analysis]
|
| 86 |
Romano B, Lleo A, Sala E, D’amico G, Marino DI, Ciccocioppo R, Vetrano S. Mesenchymal Stem Cells to Treat Digestive System Disorders: Progress Made and Future Directions. Curr Transpl Rep 2019;6:134-45. [DOI: 10.1007/s40472-019-00238-1] [Reference Citation Analysis]
|
| 87 |
Saito D, Matsuura M, Ozaki R, Tokunaga S, Minowa S, Mitsui T, Miura M, Sakuraba A, Hayashida M, Miyoshi J, Hisamatsu T. Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis. JGH Open 2021;5:1056-62. [PMID: 34584975 DOI: 10.1002/jgh3.12630] [Reference Citation Analysis]
|
| 88 |
D’Aoust J, Battat R, Bessissow T. Management of inflammatory bowel disease with Clostridium difficile infection. World J Gastroenterol 2017; 23(27): 4986-5003 [PMID: 28785153 DOI: 10.3748/wjg.v23.i27.4986] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 89 |
Rezaei N, Eftekhari MH, Tanideh N, Mokhtari M, Bagheri Z. Comparison of Antioxidant and Anti-Inflammatory Effects of Honey and Spirulina platensis with Sulfasalazine and Mesalazine on Acetic Acid-Induced Ulcerative Colitis in Rats. Galen Med J 2019;8:e1095. [PMID: 34466462 DOI: 10.31661/gmj.v8i0.1095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 90 |
Dang X, Xu M, Liu D, Zhou D, Yang W. Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: A systematic review and meta-analysis. PLoS One. 2020;15:e0228846. [PMID: 32182248 DOI: 10.1371/journal.pone.0228846] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 91 |
Hayashi R, Ueno Y, Tanaka S, Wakai M, Kumada J, Fujita A, Nomura M, Oka S, Ito M, Chayama K. Rectal Lymphoid Follicle Aphthous Lesions Frequently Progress to Ulcerative Colitis with Proximal Extension. Intern Med 2019;58:625-31. [PMID: 30333412 DOI: 10.2169/internalmedicine.1635-18] [Reference Citation Analysis]
|
| 92 |
Kim ES, Kim KO, Jang BI, Kim EY, Lee YJ, Lee HS, Jeon SW, Kim HJ, Kim SK; Crohn’s and Colitis Association in Daegu-Gyeongbuk (CCAiD). Comparison of 4-L Polyethylene Glycol and 2-L Polyethylene Glycol Plus Ascorbic Acid in Patients with Inactive Ulcerative Colitis. Dig Dis Sci 2017;62:2489-97. [PMID: 28639128 DOI: 10.1007/s10620-017-4634-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 93 |
Colombel JF, Keir ME, Scherl A, Zhao R, de Hertogh G, Faubion WA, Lu TT. Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. Gut 2017;66:2063-8. [PMID: 27590995 DOI: 10.1136/gutjnl-2016-312307] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 94 |
Nishio M, Ishii Y, Hashimoto Y, Otake H, Ogashiwa T, Tsuda S, Yasuhara H, Saigusa Y, Kimura H, Maeda S, Kunisaki R. Short- and long-term efficacy of adalimumab salvage therapy after failure of calcineurin inhibitors in steroid-refractory ulcerative colitis. Scand J Gastroenterol 2018;53:1236-44. [PMID: 30353757 DOI: 10.1080/00365521.2018.1511825] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 95 |
Knyazev OV, Kagramanova AV, Parfenov AI. Ulcerative colitis. To the 180th anniversary of the description by Karl Rokytansky. Terapevticheskii arkhiv 2022;93:1564-8. [DOI: 10.26442/00403660.2021.12.201219] [Reference Citation Analysis]
|
| 96 |
Coskun M, Bjerrum JT, Seidelin JB, Nielsen OH. MicroRNAs in inflammatory bowel disease - pathogenesis, diagnostics and therapeutics. World J Gastroenterol 2012; 18(34): 4629-4634 [PMID: 23002331 DOI: 10.3748/wjg.v18.i34.4629] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 66] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 97 |
Zhang S, Liang Y, Yao J, Li DF, Wang LS. Role of Pyroptosis in Inflammatory Bowel Disease (IBD): From Gasdermins to DAMPs. Front Pharmacol 2022;13:833588. [PMID: 35677444 DOI: 10.3389/fphar.2022.833588] [Reference Citation Analysis]
|
| 98 |
Niederreiter L, Fritz TM, Adolph TE, Krismer AM, Offner FA, Tschurtschenthaler M, Flak MB, Hosomi S, Tomczak MF, Kaneider NC, Sarcevic E, Kempster SL, Raine T, Esser D, Rosenstiel P, Kohno K, Iwawaki T, Tilg H, Blumberg RS, Kaser A. ER stress transcription factor Xbp1 suppresses intestinal tumorigenesis and directs intestinal stem cells. J Exp Med 2013;210:2041-56. [PMID: 24043762 DOI: 10.1084/jem.20122341] [Cited by in Crossref: 89] [Cited by in F6Publishing: 86] [Article Influence: 9.9] [Reference Citation Analysis]
|
| 99 |
Nowarski R, Jackson R, Gagliani N, de Zoete MR, Palm NW, Bailis W, Low JS, Harman CC, Graham M, Elinav E, Flavell RA. Epithelial IL-18 Equilibrium Controls Barrier Function in Colitis. Cell 2015;163:1444-56. [PMID: 26638073 DOI: 10.1016/j.cell.2015.10.072] [Cited by in Crossref: 239] [Cited by in F6Publishing: 221] [Article Influence: 39.8] [Reference Citation Analysis]
|
| 100 |
Jang EC, Choi SJ, Cho JH, Ryu JS, Kwak SM, Lee HL, Nam HS. Organizing pneumonia presenting after ulcerative colitis remission. J Thorac Dis 2013;5:E71-3. [PMID: 23585964 DOI: 10.3978/j.issn.2072-1439.2013.03.11] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 101 |
Liu L, Zhao C, Yang Y, Kong X, Shao T, Ren L, Zhuang X, Yin B, Dryden G, McClain C, Luan W, Feng W. Fibroblast Growth Factor 21 Deficiency Attenuates Experimental Colitis-Induced Adipose Tissue Lipolysis. Gastroenterol Res Pract 2017;2017:3089378. [PMID: 28584524 DOI: 10.1155/2017/3089378] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 102 |
Teixeira FV, Damião AOMC, Kotze PG. TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES. Arq Gastroenterol 2018;55:198-200. [PMID: 30043874 DOI: 10.1590/S0004-2803.201800000-36] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 103 |
Wang CJ, Byun MJ, Kim S, Park W, Park HH, Kim T, Lee JS, Park CG. Biomaterials as therapeutic drug carriers for inflammatory bowel disease treatment. Journal of Controlled Release 2022. [DOI: 10.1016/j.jconrel.2022.02.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 104 |
Schmitt H, Ulmschneider J, Billmeier U, Vieth M, Scarozza P, Sonnewald S, Reid S, Atreya I, Rath T, Zundler S, Langheinrich M, Schüttler J, Hartmann A, Winkler T, Admyre C, Knittel T, Dieterich Johansson C, Zargari A, Neurath MF, Atreya R. The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis. J Crohns Colitis 2020;14:508-24. [PMID: 31630153 DOI: 10.1093/ecco-jcc/jjz170] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 105 |
Yan S, Wang P, Wei H, Jia R, Zhen M, Li Q, Xue C, Li J. Treatment of ulcerative colitis with Wu-Mei-Wan by inhibiting intestinal inflammatory response and repairing damaged intestinal mucosa. Phytomedicine 2022. [DOI: 10.1016/j.phymed.2022.154362] [Reference Citation Analysis]
|
| 106 |
Ungaro F, Rubbino F, Danese S, D'Alessio S. Actors and Factors in the Resolution of Intestinal Inflammation: Lipid Mediators As a New Approach to Therapy in Inflammatory Bowel Diseases. Front Immunol 2017;8:1331. [PMID: 29109724 DOI: 10.3389/fimmu.2017.01331] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 107 |
Doulabi MSH, Moghaddam RG, Salehzadeh A. Associations between an MDM2 gene polymorphism and ulcerative colitis by ARMS-PCR. Genomics Inform 2020;18:e9. [PMID: 32224842 DOI: 10.5808/GI.2020.18.1.e9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 108 |
Raup-Konsavage WM, Cooper TK, Yochum GS. A Role for MYC in Lithium-Stimulated Repair of the Colonic Epithelium After DSS-Induced Damage in Mice. Dig Dis Sci. 2016;61:410-422. [PMID: 26320084 DOI: 10.1007/s10620-015-3852-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 109 |
Sun M, Du B, Shi Y, Lu Y, Zhou Y, Liu B. Combined Signature of the Fecal Microbiome and Plasma Metabolome in Patients with Ulcerative Colitis. Med Sci Monit 2019;25:3303-15. [PMID: 31055592 DOI: 10.12659/MSM.916009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 110 |
Tian L, Li Y, Zhang J, Chang R, Li J, Huo L. IL-9 promotes the pathogenesis of ulcerative colitis through STAT3/SOCS3 signaling. Biosci Rep 2018;38:BSR20181521. [PMID: 30369485 DOI: 10.1042/BSR20181521] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 111 |
Yang H, Li Y, Shen S, Gan D, Han C, Wu J, Wang Z. Network Pharmacology-Based Investigation into the Mechanisms of Quyushengxin Formula for the Treatment of Ulcerative Colitis. Evid Based Complement Alternat Med 2019;2019:7870424. [PMID: 31976001 DOI: 10.1155/2019/7870424] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 112 |
Popp C, Nichita L, Voiosu T, Bastian A, Cioplea M, Micu G, Pop G, Sticlaru L, Bengus A, Voiosu A, Mateescu RB. Expression Profile of p53 and p21 in Large Bowel Mucosa as Biomarkers of Inflammatory-Related Carcinogenesis in Ulcerative Colitis. Dis Markers 2016;2016:3625279. [PMID: 27578918 DOI: 10.1155/2016/3625279] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 113 |
Couvineau A, Voisin T, Nicole P, Gratio V, Abad C, Tan YV. Orexins as Novel Therapeutic Targets in Inflammatory and Neurodegenerative Diseases. Front Endocrinol (Lausanne) 2019;10:709. [PMID: 31695678 DOI: 10.3389/fendo.2019.00709] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 114 |
Espaillat MP, Kew RR, Obeid LM. Sphingolipids in neutrophil function and inflammatory responses: Mechanisms and implications for intestinal immunity and inflammation in ulcerative colitis. Adv Biol Regul 2017;63:140-55. [PMID: 27866974 DOI: 10.1016/j.jbior.2016.11.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 115 |
Yamada A, Arakaki R, Saito M, Tsunematsu T, Kudo Y, Ishimaru N. Role of regulatory T cell in the pathogenesis of inflammatory bowel disease. World J Gastroenterol 2016; 22(7): 2195-2205 [PMID: 26900284 DOI: 10.3748/wjg.v22.i7.2195] [Cited by in CrossRef: 97] [Cited by in F6Publishing: 88] [Article Influence: 16.2] [Reference Citation Analysis]
|
| 116 |
Shafran I, Burgunder P, Wei D, Young HE, Klein G, Burnett BP. Management of inflammatory bowel disease with oral serum-derived bovine immunoglobulin. Therap Adv Gastroenterol 2015;8:331-9. [PMID: 26557889 DOI: 10.1177/1756283X15593693] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 117 |
Brunson JL, Becker F, Stokes KY. The impact of primary and persistent cytomegalovirus infection on the progression of acute colitis in a murine model. Pathophysiology 2015;22:31-7. [PMID: 25511533 DOI: 10.1016/j.pathophys.2014.11.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 118 |
Pandey M, Choudhury H, D/O Segar Singh SK, Chetty Annan N, Bhattamisra SK, Gorain B, Mohd Amin MCI. Budesonide-Loaded Pectin/Polyacrylamide Hydrogel for Sustained Delivery: Fabrication, Characterization and In Vitro Release Kinetics. Molecules 2021;26:2704. [PMID: 34062995 DOI: 10.3390/molecules26092704] [Reference Citation Analysis]
|
| 119 |
Yang C, Long D, Sung J, Alghoul Z, Merlin D. Orally Administered Natural Lipid Nanoparticle-Loaded 6-Shogaol Shapes the Anti-Inflammatory Microbiota and Metabolome. Pharmaceutics 2021;13:1355. [PMID: 34575431 DOI: 10.3390/pharmaceutics13091355] [Reference Citation Analysis]
|
| 120 |
Battat R, Dulai PS, Jairath V, Vande Casteele N. A product review of vedolizumab in inflammatory bowel disease. Hum Vaccin Immunother 2019;15:2482-90. [PMID: 30897022 DOI: 10.1080/21645515.2019.1591139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 121 |
Shi Y, Dong Y, Huang W, Zhu D, Mao H, Su P. Fecal Microbiota Transplantation for Ulcerative Colitis: A Systematic Review and Meta-Analysis. PLoS One. 2016;11:e0157259. [PMID: 27295210 DOI: 10.1371/journal.pone.0157259] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 122 |
Zhang S, Chen F, Wu J, Liu C, Yang G, Piao R, Geng B, Xu K, Liu P. Regional Gray Matter Volume Changes in Brains of Patients With Ulcerative Colitis. Inflamm Bowel Dis 2021:izab252. [PMID: 34734248 DOI: 10.1093/ibd/izab252] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 123 |
Ghouri YA, Tahan V, Shen B. Secondary causes of inflammatory bowel diseases. World J Gastroenterol 2020; 26(28): 3998-4017 [PMID: 32821067 DOI: 10.3748/wjg.v26.i28.3998] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 124 |
Besednova NN, Zaporozhets TS, Kuznetsova TA, Makarenkova ID, Kryzhanovsky SP, Fedyanina LN, Ermakova SP. Extracts and Marine Algae Polysaccharides in Therapy and Prevention of Inflammatory Diseases of the Intestine. Mar Drugs 2020;18:E289. [PMID: 32486405 DOI: 10.3390/md18060289] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 125 |
Forkel M, Mjösberg J. Dysregulation of Group 3 Innate Lymphoid Cells in the Pathogenesis of Inflammatory Bowel Disease. Curr Allergy Asthma Rep 2016;16:73. [PMID: 27645534 DOI: 10.1007/s11882-016-0652-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 126 |
Li J, Kong D, Wang Q, Wu W, Tang Y, Bai T, Guo L, Wei L, Zhang Q, Yu Y, Qian Y, Zuo S, Liu G, Liu Q, Wu S, Zang Y, Zhu Q, Jia D, Wang Y, Yao W, Ji Y, Yin H, Nakamura M, Lazarus M, Breyer RM, Wang L, Yu Y. Niacin ameliorates ulcerative colitis via prostaglandin D2-mediated D prostanoid receptor 1 activation. EMBO Mol Med 2017;9:571-88. [PMID: 28341703 DOI: 10.15252/emmm.201606987] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 127 |
Gilroy L, Allen PB. Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease? Clin Exp Gastroenterol 2014;7:163-72. [PMID: 24899819 DOI: 10.2147/CEG.S45261] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 128 |
Huang Y, Ma Z, Cui YH, Dong HS, Zhao JM, Dou CZ, Liu HR, Li J, Wu HG. Effects of Herb-Partitioned Moxibustion on the miRNA Expression Profiles in Colon from Rats with DSS-Induced Ulcerative Colitis. Evid Based Complement Alternat Med 2017;2017:1767301. [PMID: 28246536 DOI: 10.1155/2017/1767301] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 129 |
Hosseini-Asl SK, Mehrabani D, Karimi-Busheri F. Therapeutic Effect of Mesenchymal Stem Cells in Ulcerative Colitis: A Review on Achievements and Challenges. J Clin Med 2020;9:E3922. [PMID: 33287220 DOI: 10.3390/jcm9123922] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 130 |
Bates J, Diehl L. Dendritic cells in IBD pathogenesis: an area of therapeutic opportunity? J Pathol. 2014;232:112-120. [PMID: 24122796 DOI: 10.1002/path.4277] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 131 |
Tilg H, Danese S. Roseburia hominis: a novel guilty player in ulcerative colitis pathogenesis? Gut 2014;63:1204-5. [PMID: 24127511 DOI: 10.1136/gutjnl-2013-305799] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 132 |
Li XV, Leonardi I, Putzel GG, Semon A, Fiers WD, Kusakabe T, Lin WY, Gao IH, Doron I, Gutierrez-Guerrero A, DeCelie MB, Carriche GM, Mesko M, Yang C, Naglik JR, Hube B, Scherl EJ, Iliev ID. Immune regulation by fungal strain diversity in inflammatory bowel disease. Nature 2022. [PMID: 35296857 DOI: 10.1038/s41586-022-04502-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 133 |
Wu P, Jia F, Zhang B, Zhang P. Risk of cardiovascular disease in inflammatory bowel disease. Exp Ther Med 2017;13:395-400. [PMID: 28352306 DOI: 10.3892/etm.2016.3966] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 134 |
Trivedi PJ, Bruns T, Ward S, Mai M, Schmidt C, Hirschfield GM, Weston CJ, Adams DH. Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity. J Autoimmun 2016;68:98-104. [PMID: 26873648 DOI: 10.1016/j.jaut.2016.01.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 135 |
Yang Y, Yan H, Jing M, Zhang Z, Zhang G, Sun Y, Shan L, Yu P, Wang Y, Xu L. Andrographolide derivative AL-1 ameliorates TNBS-induced colitis in mice: involvement of NF-кB and PPAR-γ signaling pathways. Sci Rep 2016;6:29716. [PMID: 27435110 DOI: 10.1038/srep29716] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 136 |
Arora Z, Shen B. Biological therapy for ulcerative colitis. Gastroenterol Rep (Oxf) 2015;3:103-9. [PMID: 25344680 DOI: 10.1093/gastro/gou070] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 137 |
Detrez I, Dreesen E, Van Stappen T, de Vries A, Brouwers E, Van Assche G, Vermeire S, Ferrante M, Gils A. Variability in Golimumab Exposure: A ‘Real-Life’ Observational Study in Active Ulcerative Colitis. J Crohns Colitis. 2016;10:575-581. [PMID: 26738756 DOI: 10.1093/ecco-jcc/jjv241] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 138 |
Hong MY, Tseng Y, Kalaba M, Beidler J. Effects of watermelon powder supplementation on colitis in high-fat diet-fed and dextran sodium sulfate-treated rats. Journal of Functional Foods 2019;54:520-8. [DOI: 10.1016/j.jff.2019.02.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 139 |
Cader MZ, Kaser A. Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut 2013;62:1653-64. [PMID: 24104886 DOI: 10.1136/gutjnl-2012-303955] [Cited by in Crossref: 218] [Cited by in F6Publishing: 209] [Article Influence: 24.2] [Reference Citation Analysis]
|
| 140 |
Zhang X, Deng QH, Deng JH, Wang SJ, Chen Q. Lovastatin derivative dehydrolovastatin ameliorates ulcerative colitis in mice by suppressing NF-κB and inflammatory cytokine expression. Korean J Physiol Pharmacol 2020;24:137-47. [PMID: 32140037 DOI: 10.4196/kjpp.2020.24.2.137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 141 |
Nyboe Andersen N, Gørtz S, Frisch M, Jess T. Reduced risk of UC in families affected by appendicitis: a Danish national cohort study. Gut 2017;66:1398-402. [PMID: 27196591 DOI: 10.1136/gutjnl-2015-311131] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 142 |
Thuy-Boun PS, Wolan DW. A glycal-based photoaffinity probe that enriches sialic acid binding proteins. Bioorg Med Chem Lett 2019;29:2609-12. [PMID: 31387789 DOI: 10.1016/j.bmcl.2019.07.054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 143 |
Tian Y, Li JX, Li YX, Wang HH, Liu XG. Clinical characteristics of ulcerative colitis with ankylosing spondylitis vs sacroiliitis with ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2013; 21(14): 1355-1359 [DOI: 10.11569/wcjd.v21.i14.1355] [Reference Citation Analysis]
|
| 144 |
Hudson LE, Anderson SE, Corbett AH, Lamb TJ. Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. Clin Microbiol Rev. 2017;30:191-231. [PMID: 27856521 DOI: 10.1128/cmr.00049-16] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 7.6] [Reference Citation Analysis]
|
| 145 |
Liu YJ, Xu WH, Fan LM, Zhang YQ, Xu W, Chen YP, Chen LL, Chen L, Xu W, Wang Y, Chu KD, Zhang JP. Polydatin alleviates DSS- and TNBS-induced colitis by suppressing Th17 cell differentiation via directly inhibiting STAT3. Phytother Res 2022. [PMID: 35766233 DOI: 10.1002/ptr.7533] [Reference Citation Analysis]
|
| 146 |
Markovic M, Dahan A, Keinan S, Kurnikov I, Aponick A, Zimmermann EM, Ben-Shabat S. Phospholipid-Based Prodrugs for Colon-Targeted Drug Delivery: Experimental Study and In-Silico Simulations. Pharmaceutics 2019;11:E186. [PMID: 30995772 DOI: 10.3390/pharmaceutics11040186] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 147 |
Schey R, Dornhoff H, Baier JL, Purtak M, Opoka R, Koller AK, Atreya R, Rau TT, Daniel C, Amann K. CD101 inhibits the expansion of colitogenic T cells. Mucosal Immunol. 2016;9:1205-1217. [PMID: 26813346 DOI: 10.1038/mi.2015.139] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 148 |
Zhu C, Song K, Shen Z, Quan Y, Tan B, Luo W, Wu S, Tang K, Yang Z, Wang X. Roseburia intestinalis inhibits interleukin‑17 excretion and promotes regulatory T cells differentiation in colitis. Mol Med Rep 2018;17:7567-74. [PMID: 29620246 DOI: 10.3892/mmr.2018.8833] [Cited by in Crossref: 10] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 149 |
Michail S, Durbin M, Turner D, Griffiths AM, Mack DR, Hyams J, Leleiko N, Kenche H, Stolfi A, Wine E. Alterations in the gut microbiome of children with severe ulcerative colitis. Inflamm Bowel Dis. 2012;18:1799-1808. [PMID: 22170749 DOI: 10.1002/ibd.22860] [Cited by in Crossref: 194] [Cited by in F6Publishing: 174] [Article Influence: 17.6] [Reference Citation Analysis]
|
| 150 |
Blander JM. Death in the intestinal epithelium-basic biology and implications for inflammatory bowel disease. FEBS J. 2016;283:2720-2730. [PMID: 27250564 DOI: 10.1111/febs.13771] [Cited by in Crossref: 83] [Cited by in F6Publishing: 74] [Article Influence: 13.8] [Reference Citation Analysis]
|
| 151 |
Neurath MF. New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol. 2014;7:6-19. [PMID: 24084775 DOI: 10.1038/mi.2013.73] [Cited by in Crossref: 192] [Cited by in F6Publishing: 188] [Article Influence: 21.3] [Reference Citation Analysis]
|
| 152 |
Fellermann K, Schiefke I, Rácz I, Derova J, Jonaitis L, Wehrum S, Nacak T, Greinwald R. Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1). United European Gastroenterol J 2020;8:1186-95. [PMID: 33028169 DOI: 10.1177/2050640620962632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 153 |
Yao HF, Shen H, Zheng K, Zhu L. Plasma and colonic mucosal levels of IL-23 and IL-17 in patients with ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2013; 21(29): 3153-3157 [DOI: 10.11569/wcjd.v21.i29.3153] [Reference Citation Analysis]
|
| 154 |
Henson MA, Phalak P. Microbiota dysbiosis in inflammatory bowel diseases: in silico investigation of the oxygen hypothesis. BMC Syst Biol 2017;11:145. [PMID: 29282051 DOI: 10.1186/s12918-017-0522-1] [Cited by in F6Publishing: 27] [Reference Citation Analysis]
|
| 155 |
Lohan C, Diamantopoulos A, LeReun C, Wright E, Bohm N, Sawyer LM. Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. BMJ Open Gastroenterol 2019;6:e000302. [PMID: 31413856 DOI: 10.1136/bmjgast-2019-000302] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 156 |
Wang S, Bai M, Shu Q, Liu Z, Shao Y, Xu K, Xiong X, Liu H, Li Y. Modulating Effect of Paeonol on Piglets With Ulcerative Colitis. Front Nutr 2022;9:846684. [DOI: 10.3389/fnut.2022.846684] [Reference Citation Analysis]
|
| 157 |
Neufert C, Becker C, Türeci Ö, Waldner MJ, Backert I, Floh K, Atreya I, Leppkes M, Jefremow A, Vieth M. Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK. J Clin Invest. 2013;123:1428-1443. [PMID: 23549083 DOI: 10.1172/jci63748] [Cited by in Crossref: 71] [Cited by in F6Publishing: 47] [Article Influence: 7.9] [Reference Citation Analysis]
|
| 158 |
Decara J, Rivera P, López-Gambero AJ, Serrano A, Pavón FJ, Baixeras E, Rodríguez de Fonseca F, Suárez J. Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases. Front Pharmacol 2020;11:730. [PMID: 32536865 DOI: 10.3389/fphar.2020.00730] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 159 |
Hu H, Lei Y, Zhang W, Xiong P, Song L, Luo X, Jia B, Zhang F. Anti-inflammatory activity and safety of compound glycyrrhizin in ulcerative colitis: A systematic review and meta-analysis of randomized controlled trials. Journal of Functional Foods 2022;91:105004. [DOI: 10.1016/j.jff.2022.105004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 160 |
Sun T, Kwong CHT, Gao C, Wei J, Yue L, Zhang J, Ye RD, Wang R. Amelioration of ulcerative colitis via inflammatory regulation by macrophage-biomimetic nanomedicine. Theranostics 2020;10:10106-19. [PMID: 32929337 DOI: 10.7150/thno.48448] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 161 |
Ito G, Okamoto R, Murano T, Shimizu H, Fujii S, Nakata T, Mizutani T, Yui S, Akiyama-Morio J, Nemoto Y, Okada E, Araki A, Ohtsuka K, Tsuchiya K, Nakamura T, Watanabe M. Lineage-specific expression of bestrophin-2 and bestrophin-4 in human intestinal epithelial cells. PLoS One. 2013;8:e79693. [PMID: 24223998 DOI: 10.1371/journal.pone.0079693] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 162 |
Dudley-Brown S. Optimizing Inflammatory Bowel Disease Management: An Overview for the Gastroenterology Nurse. Gastroenterol Nurs 2017;40 Suppl 1S:S1-S14. [PMID: 27922458 DOI: 10.1097/SGA.0000000000000277] [Reference Citation Analysis]
|
| 163 |
Koukos G, Polytarchou C, Kaplan JL, Morley-Fletcher A, Gras-Miralles B, Kokkotou E, Baril-Dore M, Pothoulakis C, Winter HS, Iliopoulos D. MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis. Gastroenterology. 2013;145:842-852.e2. [PMID: 23856509 DOI: 10.1053/j.gastro.2013.07.001] [Cited by in Crossref: 139] [Cited by in F6Publishing: 146] [Article Influence: 15.4] [Reference Citation Analysis]
|
| 164 |
Mao TY, Shi R, Zhao WH, Guo Y, Gao KL, Chen C, Xie TH, Li JX. Qingchang Wenzhong Decoction Ameliorates Dextran Sulphate Sodium-Induced Ulcerative Colitis in Rats by Downregulating the IP10/CXCR3 Axis-Mediated Inflammatory Response. Evid Based Complement Alternat Med 2016;2016:4312538. [PMID: 27413386 DOI: 10.1155/2016/4312538] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 165 |
Atreya R, Neurath MF. Current and Future Targets for Mucosal Healing in Inflammatory Bowel Disease. Visc Med. 2017;33:82-88. [PMID: 28612022 DOI: 10.1159/000458006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 166 |
Wang MH, Fiocchi C, Zhu X, Ripke S, Kamboh MI, Rebert N, Duerr RH, Achkar JP. Gene-gene and gene-environment interactions in ulcerative colitis. Hum Genet. 2014;133:547-558. [PMID: 24241240 DOI: 10.1007/s00439-013-1395-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 167 |
Abdelmahmuod EA, Ali E, Ahmed MA, Yassin MA. Eltrombopag and its beneficial role in management of ulcerative Colitis associated with ITP as an upfront therapy case report. Clin Case Rep 2021;9:1416-9. [PMID: 33768857 DOI: 10.1002/ccr3.3783] [Reference Citation Analysis]
|
| 168 |
Vidal-Lletjós S, Andriamihaja M, Blais A, Grauso M, Lepage P, Davila AM, Viel R, Gaudichon C, Leclerc M, Blachier F, Lan A. Dietary Protein Intake Level Modulates Mucosal Healing and Mucosa-Adherent Microbiota in Mouse Model of Colitis. Nutrients 2019;11:E514. [PMID: 30823387 DOI: 10.3390/nu11030514] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 169 |
Larussa T, Oliverio M, Suraci E, Greco M, Placida R, Gervasi S, Marasco R, Imeneo M, Paolino D, Tucci L, Gulletta E, Fresta M, Procopio A, Luzza F. Oleuropein Decreases Cyclooxygenase-2 and Interleukin-17 Expression and Attenuates Inflammatory Damage in Colonic Samples from Ulcerative Colitis Patients. Nutrients 2017;9:E391. [PMID: 28420140 DOI: 10.3390/nu9040391] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 170 |
Freeman HJ. Medical management of ulcerative colitis with a specific focus on 5-aminosalicylates. Clin Med Insights Gastroenterol 2012;5:77-83. [PMID: 24833937 DOI: 10.4137/CGast.S8673] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 171 |
Arora Z, Mukewar S, Wu X, Shen B. Risk factors and clinical implication of superimposed Campylobacter jejuni infection in patients with underlying ulcerative colitis. Gastroenterol Rep (Oxf). 2016;4:287-292. [PMID: 26159630 DOI: 10.1093/gastro/gov029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 172 |
Farkas K, Molnár T. Novel extended release budesonide formulation for treatment of ulcerative colitis. Expert Opin Pharmacother 2014;15:131-7. [PMID: 24219763 DOI: 10.1517/14656566.2014.860444] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 173 |
Yang X, Geng J, Meng H. Glucocorticoid receptor modulates dendritic cell function in ulcerative colitis. Histol Histopathol 2020;35:1379-89. [PMID: 32706033 DOI: 10.14670/HH-18-241] [Reference Citation Analysis]
|
| 174 |
Takahara M, Hiraoka S, Ohmori M, Takeuchi K, Takei K, Yasutomi E, Igawa S, Yamamoto S, Yamasaki Y, Inokuchi T, Kinugasa H, Harada K, Ohnishi H, Okada H. The Colon Wall Thickness Measured Using Transabdominal Ultrasonography is Useful for Detecting Mucosal Inflammation in Ulcerative Colitis. Intern Med . [DOI: 10.2169/internalmedicine.8827-21] [Reference Citation Analysis]
|
| 175 |
Sood R, Daw HA. Pleomorphic malignant histiocytoma: a rare skin cancer in a patient on azathioprine for ulcerative colitis. BMJ Case Rep 2012;2012:bcr0320125957. [PMID: 22761209 DOI: 10.1136/bcr.03.2012.5957] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 176 |
Biancheri P, Foster MR, Fyfe MC, MacDonald TT, Sirohi S, Solanke Y, Wood E, Rowley A, Webber S, Walshe CA. Effect of Narrow Spectrum Versus Selective Kinase Inhibitors on the Intestinal Proinflammatory Immune Response in Ulcerative Colitis. Inflamm Bowel Dis 2016;22:1306-15. [PMID: 27104822 DOI: 10.1097/MIB.0000000000000759] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 177 |
Ma Y, Hu C, Yan W, Jiang H, Liu G. Lactobacillus pentosus Increases the Abundance of Akkermansia and Affects the Serum Metabolome to Alleviate DSS-Induced Colitis in a Murine Model. Front Cell Dev Biol 2020;8:591408. [PMID: 33195257 DOI: 10.3389/fcell.2020.591408] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 178 |
Yao D, Dai W, Dong M, Dai C, Wu S. MUC2 and related bacterial factors: Therapeutic targets for ulcerative colitis. EBioMedicine 2021;74:103751. [PMID: 34902790 DOI: 10.1016/j.ebiom.2021.103751] [Reference Citation Analysis]
|
| 179 |
Chi HG, Zheng XB, Wu ZG, Dai SX, Wan Z, Zou Y. Association of the interleukin-22 genetic polymorphisms with ulcerative colitis. Diagn Pathol 2014;9:183. [PMID: 25297677 DOI: 10.1186/s13000-014-0183-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 180 |
Hayashi R, Ueno Y, Tanaka S, Onishi K, Takasago T, Wakai M, Naito T, Sasaki K, Doi S, Masaki T, Chayama K. Clinical characteristics of inflammatory bowel disease patients with immunoglobulin A nephropathy. Intest Res 2021;19:430-7. [PMID: 33153254 DOI: 10.5217/ir.2020.00067] [Reference Citation Analysis]
|
| 181 |
Choo J, Lee Y, Yan XJ, Noh TH, Kim SJ, Son S, Pothoulakis C, Moon HR, Jung JH, Im E. A Novel Peroxisome Proliferator-activated Receptor (PPAR)γ Agonist 2-Hydroxyethyl 5-chloro-4,5-didehydrojasmonate Exerts Anti-Inflammatory Effects in Colitis. J Biol Chem 2015;290:25609-19. [PMID: 26342083 DOI: 10.1074/jbc.M115.673046] [Cited by in Crossref: 38] [Cited by in F6Publishing: 16] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 182 |
Zundler S, Schillinger D, Fischer A, Atreya R, López-Posadas R, Watson A, Neufert C, Atreya I, Neurath MF. Blockade of αEβ7 integrin suppresses accumulation of CD8+ and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo. Gut 2017;66:1936-48. [PMID: 27543429 DOI: 10.1136/gutjnl-2016-312439] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 183 |
Kim JW, Kim HJ, Lee CK, Shim JJ, Jang JY, Dong SH, Kim BH, Chang YW, Chi SG. Elevation of PRKCDBP, a novel transcriptional target of TNF-α, and its downregulation by infliximab in patients with ulcerative colitis. Dig Dis Sci 2014;59:2947-57. [PMID: 25052149 DOI: 10.1007/s10620-014-3282-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 184 |
Varyani F, Fleming JO, Maizels RM. Helminths in the gastrointestinal tract as modulators of immunity and pathology. Am J Physiol Gastrointest Liver Physiol 2017;312:G537-49. [PMID: 28302598 DOI: 10.1152/ajpgi.00024.2017] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 9.2] [Reference Citation Analysis]
|
| 185 |
Xing G, Zhang Y, Wu X, Wang H, Liu Y, Zhang Z, Hou M, Hua H. Analysis of the Efficacy and Pharmacological Mechanisms of Action of Zhenren Yangzang Decoction on Ulcerative Colitis Using Meta-Analysis and Network Pharmacology. Evid Based Complement Alternat Med 2021;2021:4512755. [PMID: 34992665 DOI: 10.1155/2021/4512755] [Reference Citation Analysis]
|
| 186 |
Fiorino G, Gilardi D, Danese S. The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes. Therap Adv Gastroenterol 2016;9:503-12. [PMID: 27366219 DOI: 10.1177/1756283X16647935] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 187 |
Wu W, He Y, Feng X, Ye S, Wang H, Tan W, Yu C, Hu J, Zheng R, Zhou Y. MicroRNA-206 is involved in the pathogenesis of ulcerative colitis via regulation of adenosine A3 receptor. Oncotarget 2017;8:705-21. [PMID: 27893428 DOI: 10.18632/oncotarget.13525] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 188 |
Ignacio A, Morales CI, Câmara NO, Almeida RR. Innate Sensing of the Gut Microbiota: Modulation of Inflammatory and Autoimmune Diseases. Front Immunol 2016;7:54. [PMID: 26925061 DOI: 10.3389/fimmu.2016.00054] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 189 |
Zhang Y, Li X, Luo Z, Ma L, Zhu S, Wang Z, Wen J, Cheng S, Gu W, Lian Q, Zhao X, Fan W, Ling Z, Ye J, Zheng S, Li D, Wang H, Liu J, Sun B. ECM1 is an essential factor for the determination of M1 macrophage polarization in IBD in response to LPS stimulation. Proc Natl Acad Sci U S A 2020;117:3083-92. [PMID: 31980528 DOI: 10.1073/pnas.1912774117] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 190 |
Collins MH, Martin LJ, Alexander ES, Boyd JT, Sheridan R, He H, Pentiuk S, Putnam PE, Abonia JP, Mukkada VA, Franciosi JP, Rothenberg ME. Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring. Dis Esophagus. 2017;30:1-8. [PMID: 26857345 DOI: 10.1111/dote.12470] [Cited by in Crossref: 29] [Cited by in F6Publishing: 74] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 191 |
Polytarchou C, Hommes DW, Palumbo T, Hatziapostolou M, Koutsioumpa M, Koukos G, van der Meulen-de Jong AE, Oikonomopoulos A, van Deen WK, Vorvis C. MicroRNA214 Is Associated With Progression of Ulcerative Colitis, and Inhibition Reduces Development of Colitis and Colitis-Associated Cancer in Mice. Gastroenterology. 2015;149:981-92.e11. [PMID: 26055138 DOI: 10.1053/j.gastro.2015.05.057] [Cited by in Crossref: 77] [Cited by in F6Publishing: 81] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 192 |
Oncel S, Basson MD. Gut homeostasis, injury, and healing: New therapeutic targets. World J Gastroenterol 2022; 28(17): 1725-1750 [DOI: 10.3748/wjg.v28.i17.1725] [Reference Citation Analysis]
|
| 193 |
Koch Hansen L, Sevelsted-Møller L, Rabjerg M, Larsen D, Hansen TP, Klinge L, Wulff H, Knudsen T, Kjeldsen J, Köhler R. Expression of T-cell KV1.3 potassium channel correlates with pro-inflammatory cytokines and disease activity in ulcerative colitis. J Crohns Colitis 2014;8:1378-91. [PMID: 24793818 DOI: 10.1016/j.crohns.2014.04.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 194 |
Saber T, Bedran K, Ghandour F, El Khoury M, Bou Khalil R, Farhat S. Results from a retrospective analysis of colonoscopies for Inflammatory bowel disease and colorectal cancer in a Lebanese tertiary care centre. BMJ Open Gastroenterol 2017;4:e000167. [PMID: 29018541 DOI: 10.1136/bmjgast-2017-000167] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 195 |
Ou AT, Zhang JX, Fang YF, Wang R, Tang XP, Zhao PF, Zhao YG, Zhang M, Huang YZ. Disulfiram-loaded lactoferrin nanoparticles for treating inflammatory diseases. Acta Pharmacol Sin 2021;42:1913-20. [PMID: 34561552 DOI: 10.1038/s41401-021-00770-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 196 |
Pimentel GD, Micheletti TO, Pace F, Rosa JC, Santos RV, Lira FS. Gut-central nervous system axis is a target for nutritional therapies. Nutr J 2012;11:22. [PMID: 22490672 DOI: 10.1186/1475-2891-11-22] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 197 |
Sendon-Lago J, Rio LG, Eiro N, Diaz-Rodriguez P, Avila L, Gonzalez LO, Vizoso FJ, Perez-Fernandez R, Landin M. Tailored Hydrogels as Delivery Platforms for Conditioned Medium from Mesenchymal Stem Cells in a Model of Acute Colitis in Mice. Pharmaceutics 2021;13:1127. [PMID: 34452089 DOI: 10.3390/pharmaceutics13081127] [Reference Citation Analysis]
|
| 198 |
Gordon MH, Anowai A, Young D, Das N, Campden RI, Sekhon H, Myers Z, Mainoli B, Chopra S, Thuy-Boun PS, Kizhakkedathu J, Bindra G, Jijon HB, Heitman S, Yates R, Wolan DW, Edgington-Mitchell LE, MacNaughton WK, Dufour A. N-Terminomics/TAILS Profiling of Proteases and Their Substrates in Ulcerative Colitis. ACS Chem Biol 2019;14:2471-83. [PMID: 31393699 DOI: 10.1021/acschembio.9b00608] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 199 |
Holleran G, Lopetuso L, Petito V, Graziani C, Ianiro G, McNamara D, Gasbarrini A, Scaldaferri F. The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease. Int J Mol Sci. 2017;18. [PMID: 28934123 DOI: 10.3390/ijms18102020] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 200 |
Schuster AT, Homer CR, Kemp JR, Nickerson KP, Deutschman E, Kim Y, West G, Sadler T, Stylianou E, Krokowski D, Hatzoglou M, de la Motte C, Rubin BP, Fiocchi C, McDonald C, Longworth MS. Chromosome-associated protein D3 promotes bacterial clearance in human intestinal epithelial cells by repressing expression of amino acid transporters. Gastroenterology. 2015;148:1405-1416.e3. [PMID: 25701737 DOI: 10.1053/j.gastro.2015.02.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 201 |
Adegoke GA, Onasanwo SA, Eyarefe OD, Olaleye SB. Ameliorative effects of Musa sapientum peel extract on acetic acid-induced colitis in rats. The Journal of Basic & Applied Zoology 2016;77:49-55. [DOI: 10.1016/j.jobaz.2016.06.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 202 |
Hozumi H, Hokari R, Kurihara C, Narimatsu K, Sato H, Sato S, Ueda T, Higashiyama M, Okada Y, Watanabe C, Komoto S, Tomita K, Kawaguchi A, Nagao S, Miura S. Endoscopic finding of spontaneous hemorrhage correlates with tumor necrosis factor alpha expression in colonic mucosa of patients with ulcerative colitis. Int J Colorectal Dis 2013;28:1049-55. [PMID: 23377880 DOI: 10.1007/s00384-013-1654-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 203 |
Maranville JC, Baxter SS, Witonsky DB, Chase MA, Di Rienzo A. Genetic mapping with multiple levels of phenotypic information reveals determinants of lymphocyte glucocorticoid sensitivity. Am J Hum Genet 2013;93:735-43. [PMID: 24055111 DOI: 10.1016/j.ajhg.2013.08.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 204 |
Travis S, Feagan BG, Peyrin-Biroulet L, Panaccione R, Danese S, Lazar A, Robinson AM, Petersson J, Pappalardo BL, Bereswill M, Chen N, Wang S, Skup M, Thakkar RB, Chao J. Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA. J Crohns Colitis 2017;11:1317-25. [PMID: 28981846 DOI: 10.1093/ecco-jcc/jjx093] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 205 |
Kim H, Castellon-Chicas MJ, Arbizu S, Talcott ST, Drury NL, Smith S, Mertens-Talcott SU. Mango (Mangifera indica L.) Polyphenols: Anti-Inflammatory Intestinal Microbial Health Benefits, and Associated Mechanisms of Actions. Molecules 2021;26:2732. [PMID: 34066494 DOI: 10.3390/molecules26092732] [Reference Citation Analysis]
|
| 206 |
Mosli MH, Al-Harbi O, Feagan BG, Almadi MA. A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease. Saudi J Gastroenterol. 2015;21:185-197. [PMID: 26228361 DOI: 10.4103/1319-3767.161635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 207 |
Himmel ME, Yao Y, Orban PC, Steiner TS, Levings MK. Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers. Immunology. 2012;136:115-122. [PMID: 22348589 DOI: 10.1111/j.1365-2567.2012.03572.x.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 208 |
Liu CC, Zhang ZY. Relationship between cytomegalovirus infection and inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2015; 23(11): 1784-1790 [DOI: 10.11569/wcjd.v23.i11.1784] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 209 |
Dignass A, Akbar A, Hart A, Subramanian S, Bommelaer G, Baumgart DC, Grimaud JC, Cadiot G, Makins R, Hoque S, Bouguen G, Bonaz B. Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results. J Crohns Colitis. 2016;10:812-820. [PMID: 26818659 DOI: 10.1093/ecco-jcc/jjw032] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 210 |
Montrose DC, Zhou XK, McNally EM, Sue E, Wang H, Nishiguchi R, Verma A, Elemento O, Simpson KW, Yang P, Hla T, Dannenberg AJ. Colonoscopic-Guided Pinch Biopsies in Mice as a Useful Model for Evaluating the Roles of Host and Luminal Factors in Colonic Inflammation. Am J Pathol 2018;188:2811-25. [PMID: 30273600 DOI: 10.1016/j.ajpath.2018.08.016] [Reference Citation Analysis]
|
| 211 |
Ruder B, Becker C. At the Forefront of the Mucosal Barrier: The Role of Macrophages in the Intestine. Cells 2020;9:E2162. [PMID: 32987848 DOI: 10.3390/cells9102162] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 212 |
Groshek J, Basil M, Guo L, Parker Ward S, Farraye FA, Reich J. Media Consumption and Creation in Attitudes Toward and Knowledge of Inflammatory Bowel Disease: Web-Based Survey. J Med Internet Res 2017;19:e403. [PMID: 29222081 DOI: 10.2196/jmir.7624] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 213 |
Nakase H, Sato N, Mizuno N, Ikawa Y. The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun Rev 2021;:103017. [PMID: 34902606 DOI: 10.1016/j.autrev.2021.103017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 214 |
Boyapati RK, Rossi AG, Satsangi J, Ho GT. Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications. Mucosal Immunol. 2016;9:567-582. [PMID: 26931062 DOI: 10.1038/mi.2016.14] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 10.2] [Reference Citation Analysis]
|
| 215 |
Ho GT, Aird RE, Liu B, Boyapati RK, Kennedy NA, Dorward DA, Noble CL, Shimizu T, Carter RN, Chew ETS, Morton NM, Rossi AG, Sartor RB, Iredale JP, Satsangi J. MDR1 deficiency impairs mitochondrial homeostasis and promotes intestinal inflammation. Mucosal Immunol 2018;11:120-30. [PMID: 28401939 DOI: 10.1038/mi.2017.31] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 216 |
Schweda A, Becker E, Wiendl M, Atreya R, Atreya I, Müller TM, Neurath MF, Zundler S. Etrolizumab-s Does Not Induce Residual Trafficking of Regulatory T Cells. Inflamm Bowel Dis 2022:izac137. [PMID: 35815779 DOI: 10.1093/ibd/izac137] [Reference Citation Analysis]
|
| 217 |
Alsaleh A, Gaidos JK, Kang L, Kuemmerle JF. Timing of Last Preoperative Dose of Infliximab Does Not Increase Postoperative Complications in Inflammatory Bowel Disease Patients. Dig Dis Sci 2016;61:2602-7. [PMID: 27126205 DOI: 10.1007/s10620-016-4171-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 218 |
Wang JQ, Huang Y. Serological markers of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2013; 21(36): 4110-4115 [DOI: 10.11569/wcjd.v21.i36.4110] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 219 |
Jin Y, Blikslager AT. The Regulation of Intestinal Mucosal Barrier by Myosin Light Chain Kinase/Rho Kinases. Int J Mol Sci 2020;21:E3550. [PMID: 32443411 DOI: 10.3390/ijms21103550] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 220 |
Vetter M, Neurath MF. Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges. Therap Adv Gastroenterol 2017;10:773-90. [PMID: 29051788 DOI: 10.1177/1756283X17727388] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 221 |
Scioli MG, Stasi MA, Passeri D, Doldo E, Costanza G, Camerini R, Fociani P, Arcuri G, Lombardo K, Pace S, Borsini F, Orlandi A. Propionyl-L-Carnitine is Efficacious in Ulcerative Colitis Through its Action on the Immune Function and Microvasculature. Clin Transl Gastroenterol. 2014;5:e55. [PMID: 24646507 DOI: 10.1038/ctg.2014.4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 222 |
Wirtz S, Popp V, Kindermann M, Gerlach K, Weigmann B, Fichtner-Feigl S, Neurath MF. Chemically induced mouse models of acute and chronic intestinal inflammation. Nat Protoc. 2017;12:1295-1309. [PMID: 28569761 DOI: 10.1038/nprot.2017.044] [Cited by in Crossref: 333] [Cited by in F6Publishing: 338] [Article Influence: 66.6] [Reference Citation Analysis]
|
| 223 |
Colombel JF, Sandborn WJ, Ghosh S, Wolf DC, Panaccione R, Feagan B, Reinisch W, Robinson AM, Lazar A, Kron M, Huang B, Skup M, Thakkar RB. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014;109:1771-1780. [PMID: 25155227 DOI: 10.1038/ajg.2014.242] [Cited by in Crossref: 86] [Cited by in F6Publishing: 79] [Article Influence: 10.8] [Reference Citation Analysis]
|
| 224 |
Han Y, Zhang L, Li W, Liu X, Xiao J, Chen G, Li N. Natural CAC chemopreventive agents from Ilex rotunda Thunb. J Nat Med 2019;73:456-67. [PMID: 30758715 DOI: 10.1007/s11418-019-01281-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 225 |
Han Z, Wang H, Guo D, Zhang J. Integrative transcriptomic and metabonomic profiling analyses reveal the molecular mechanism of Chinese traditional medicine huankuile suspension on TNBS-induced ulcerative colitis. Aging (Albany NY) 2021;13:5087-103. [PMID: 33535180 DOI: 10.18632/aging.202427] [Reference Citation Analysis]
|
| 226 |
Ochsenkühn T, Tillack C, Szokodi D, Janelidze S, Schnitzler F. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis. United European Gastroenterol J 2020;8:91-8. [PMID: 32213052 DOI: 10.1177/2050640619895361] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 227 |
Integrative HMP (iHMP) Research Network Consortium. The Integrative Human Microbiome Project: dynamic analysis of microbiome-host omics profiles during periods of human health and disease. Cell Host Microbe. 2014;16:276-289. [PMID: 25211071 DOI: 10.1016/j.chom.2014.08.014] [Cited by in Crossref: 272] [Cited by in F6Publishing: 214] [Article Influence: 38.9] [Reference Citation Analysis]
|
| 228 |
Poddar D, Kaur R, Baldwin WM 3rd, Mazumder B. L13a-dependent translational control in macrophages limits the pathogenesis of colitis. Cell Mol Immunol 2016;13:816-27. [PMID: 26166763 DOI: 10.1038/cmi.2015.53] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 229 |
Annese V, Rogai F, Settesoldi A, Bagnoli S. PPARγ in Inflammatory Bowel Disease. PPAR Res 2012;2012:620839. [PMID: 22997506 DOI: 10.1155/2012/620839] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 230 |
Xu J, Tam M, Samaei S, Lerouge S, Barralet J, Stevenson MM, Cerruti M. Mucoadhesive chitosan hydrogels as rectal drug delivery vessels to treat ulcerative colitis. Acta Biomater 2017;48:247-57. [PMID: 27769943 DOI: 10.1016/j.actbio.2016.10.026] [Cited by in Crossref: 84] [Cited by in F6Publishing: 62] [Article Influence: 16.8] [Reference Citation Analysis]
|
| 231 |
Neill LA, Saundry CM, Hyman NH, Wellman GC. Evidence against a systemic arterial defect in patients with inflammatory bowel disease. J Surg Res 2014;191:318-22. [PMID: 24819742 DOI: 10.1016/j.jss.2014.04.021] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 232 |
De Vries LCS, Ludbrook VJ, Hicks KJ, D'Haens GR. GSK2586184, a JAK1 selective inhibitor, in two patients with ulcerative colitis. BMJ Case Rep 2017;2017:bcr-2017-221078. [PMID: 28790099 DOI: 10.1136/bcr-2017-221078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 233 |
Chen Y, Salem M, Boyd M, Bornholdt J, Li Y, Coskun M, Seidelin JB, Sandelin A, Nielsen OH. Relation between NOD2 genotype and changes in innate signaling in Crohn's disease on mRNA and miRNA levels. NPJ Genom Med 2017;2:3. [PMID: 29263823 DOI: 10.1038/s41525-016-0001-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 234 |
Kucharzik T, Koletzko S, Kannengiesser K, Dignass A. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.Dtsch Arztebl Int. 2020;117:564-574. [PMID: 33148393 DOI: 10.3238/arztebl.2020.0564] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 235 |
Palazzo L, Mikolčević P, Mikoč A, Ahel I. ADP-ribosylation signalling and human disease. Open Biol 2019;9:190041. [PMID: 30991935 DOI: 10.1098/rsob.190041] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 236 |
Hernandez L, Kuwabara H, Shah A, Yamabe K, Burnett H, Fahrbach K, Koufopoulou M, Iwakiri R. Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan. Pharmacoeconomics 2020;38:69-84. [PMID: 31552601 DOI: 10.1007/s40273-019-00841-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 237 |
O'Hara SP, LaRusso NF. The Gut-Liver Axis in Primary Sclerosing Cholangitis: Are Pathobionts the Missing Link? Hepatology 2019;70:1058-60. [PMID: 31013359 DOI: 10.1002/hep.30673] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 238 |
Wang N, Kong R, Han W, Bao W, Shi Y, Ye L, Lu J. Honokiol alleviates ulcerative colitis by targeting PPAR-γ-TLR4-NF-κB signaling and suppressing gasdermin-D-mediated pyroptosis in vivo and in vitro. Int Immunopharmacol 2022;111:109058. [PMID: 35901530 DOI: 10.1016/j.intimp.2022.109058] [Reference Citation Analysis]
|
| 239 |
Silva FA, Rodrigues BL, Ayrizono ML, Leal RF. The Immunological Basis of Inflammatory Bowel Disease. Gastroenterol Res Pract. 2016;2016:2097274. [PMID: 28070181 DOI: 10.1155/2016/2097274] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 240 |
Barnes E, Herfarth H. Clinical features and diagnosis of ulcerative colitis. Advances in the Management of Inflammatory Bowel Disease. Unitec House: Future Medicine Ltd; 2013. pp. 50-66. [DOI: 10.2217/ebo.12.176] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 241 |
Cui DJ, Huang B, Zhu M, Ren Y. Ursodeoxycholic acid for preventing colorectal cancer in patients with ulcerative colitis: A meta-analysis. Shijie Huaren Xiaohua Zazhi 2013; 21(16): 1563-1567 [DOI: 10.11569/wcjd.v21.i16.1563] [Reference Citation Analysis]
|
| 242 |
Reinisch W, Bressler B, Curtis R, Parikh A, Yang H, Rosario M, Røseth A, Danese S, Feagan B, Sands BE, Ginsburg P, Dassopoulos T, Lewis J, Xu J, Wyant T. Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1. Inflamm Bowel Dis 2019;25:803-10. [PMID: 30295811 DOI: 10.1093/ibd/izy304] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 243 |
Valero MS, González M, Ramón-Gimenez M, Andrade PB, Moreo E, Les F, Fernandes F, Gómez-Rincón C, Berzosa C, García de Jalón JA, Arruebo MP, Plaza MÁ, Köhler R, López V, Valentão P, Castro M. Jasonia glutinosa (L.) DC., a traditional herbal medicine, reduces inflammation, oxidative stress and protects the intestinal barrier in a murine model of colitis. Inflammopharmacology 2020;28:1717-34. [PMID: 31410747 DOI: 10.1007/s10787-019-00626-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 244 |
Dotan I, Levy-Nissenbaum E, Chowers Y, Fich A, Israeli E, Adar T, Shteingart S, Soreq H, Goldin E. Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial. Dig Dis Sci 2016;61:3246-54. [PMID: 27572942 DOI: 10.1007/s10620-016-4276-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 245 |
Wang G, Hiramoto K, Ma N, Yoshikawa N, Ohnishi S, Murata M, Kawanishi S. Glycyrrhizin Attenuates Carcinogenesis by Inhibiting the Inflammatory Response in a Murine Model of Colorectal Cancer. Int J Mol Sci 2021;22:2609. [PMID: 33807620 DOI: 10.3390/ijms22052609] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 246 |
Danese S, Rudziński J, Brandt W, Dupas JL, Peyrin-Biroulet L, Bouhnik Y, Kleczkowski D, Uebel P, Lukas M, Knutsson M, Erlandsson F, Hansen MB, Keshav S. Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. Gut 2015;64:243-9. [PMID: 25304132 DOI: 10.1136/gutjnl-2014-308004] [Cited by in Crossref: 107] [Cited by in F6Publishing: 100] [Article Influence: 15.3] [Reference Citation Analysis]
|
| 247 |
Sanad MH, Gomaa NM, El Bakary NM, Ibrahim IT, Massoud A. Radioiodination of balsalazide, bioevaluation, and characterization as a highly selective radiotracer for imaging of ulcerative colitis in mice. J Labelled Comp Radiopharm 2022. [PMID: 34984721 DOI: 10.1002/jlcr.3961] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 248 |
Mavroudis G, Simren M, Jonefjäll B, Öhman L, Strid H. Symptoms compatible with functional bowel disorders are common in patients with quiescent ulcerative colitis and influence the quality of life but not the course of the disease. Therap Adv Gastroenterol 2019;12:1756284819827689. [PMID: 30815033 DOI: 10.1177/1756284819827689] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 249 |
Shaw AL, Tomanelli A, Bradshaw TP, Petschow BW, Burnett BP. Impact of serum-derived bovine immunoglobulin/protein isolate therapy on irritable bowel syndrome and inflammatory bowel disease: a survey of patient perspective. Patient Prefer Adherence 2017;11:1001-7. [PMID: 28615929 DOI: 10.2147/PPA.S134792] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 250 |
Kitayama M, Akazawa Y, Yoshikawa D, Higashi S, Morisaki T, Oda H, Ikeda M, Nakashima Y, Tabuchi M, Hashiguchi K, Matsushima K, Yamaguchi N, Kondo H, Nakao K, Takeshima F. Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naïve steroid-refractory ulcerative colitis patients. Sci Rep 2020;10:12546. [PMID: 32719413 DOI: 10.1038/s41598-020-68828-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 251 |
Nielsen OH, LaCasse EC. How genetic testing can lead to targeted management of XIAP deficiency-related inflammatory bowel disease. Genet Med 2017;19:133-43. [PMID: 27416006 DOI: 10.1038/gim.2016.82] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 252 |
Iskandar HN, Dhere T, Farraye FA. Ulcerative Colitis: Update on Medical Management. Curr Gastroenterol Rep. 2015;17:44. [PMID: 26386686 DOI: 10.1007/s11894-015-0466-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 253 |
Jefremow A, Neurath MF. New agents for immunosuppression. Best Pract Res Clin Gastroenterol 2021;54-55:101763. [PMID: 34874846 DOI: 10.1016/j.bpg.2021.101763] [Reference Citation Analysis]
|
| 254 |
Fiorino G, Bonifacio C, Allocca M, Danese S. Impact of therapies on bowel damage in Crohn's disease. United European Gastroenterol J 2020;8:410-7. [PMID: 32213030 DOI: 10.1177/2050640620908696] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 255 |
Voskens CJ, Stoica D, Roessner S, Vitali F, Zundler S, Rosenberg M, Wiesinger M, Wunder J, Siegmund B, Schuler-Thurner B, Schuler G, Berking C, Atreya R, Neurath MF. Safety and tolerability of a single infusion of autologous ex vivo expanded regulatory T cells in adults with ulcerative colitis (ER-TREG 01): protocol of a phase 1, open-label, fast-track dose-escalation clinical trial. BMJ Open 2021;11:e049208. [PMID: 34880013 DOI: 10.1136/bmjopen-2021-049208] [Reference Citation Analysis]
|
| 256 |
Lv WJ, Liu C, Li YF, Chen WQ, Li ZQ, Li Y, Xiong Y, Chao LM, Xu XL, Guo SN. Systems Pharmacology and Microbiome Dissection of Shen Ling Bai Zhu San Reveal Multiscale Treatment Strategy for IBD. Oxid Med Cell Longev 2019;2019:8194804. [PMID: 31341536 DOI: 10.1155/2019/8194804] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 257 |
Naftali T, Eindor-Abarbanel A, Ruhimovich N, Bar-Gil Shitrit A, Sklerovsky-Benjaminov F, Konikoff F, Matalon S, Shirin H, Milgrom Y, Ziv-Baran T, Broide E. The Relationship between Gender, Severity of Disease, Treatment Type, and Employment Outcome in Patients with Inflammatory Bowel Disease in Israel. Can J Gastroenterol Hepatol 2018;2018:5090849. [PMID: 30271766 DOI: 10.1155/2018/5090849] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 258 |
Vecchi M, Vernia P, Riegler G, D’Incà R, Annese V, Bagnoli S. Therapeutic landscape for ulcerative colitis: where is the Adacolumn(®) system and where should it be? Clin Exp Gastroenterol. 2013;6:1-7. [PMID: 23323022 DOI: 10.2147/ceg.s33275] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 259 |
Kothari M, Mudireddy P, Swaminath A. Patient considerations in the management of ulcerative colitis - role of vedolizumab. Ther Clin Risk Manag 2015;11:1235-42. [PMID: 26316768 DOI: 10.2147/TCRM.S65650] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 260 |
Bosca-Watts MM, Cortes X, Iborra M, Huguet JM, Sempere L, Garcia G, Gil R, Garcia M, Muñoz M, Almela P, Maroto N, Paredes JM. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study. World J Gastroenterol 2016; 22(47): 10432-10439 [PMID: 28058024 DOI: 10.3748/wjg.v22.i47.10432] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 261 |
Sandborn WJ, Bhandari BR, Randall C, Younes ZH, Romanczyk T, Xin Y, Wendt E, Chai H, McKevitt M, Zhao S, Sundy JS, Keshav S, Danese S. Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease. J Crohns Colitis 2018;12:1021-9. [PMID: 29767728 DOI: 10.1093/ecco-jcc/jjy049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 262 |
Constantin J, Atanasov P, Wirth D, Borsi A. Indirect costs associated with ulcerative colitis: a systematic literature review of real-world data. BMC Gastroenterol 2019;19:179. [PMID: 31706270 DOI: 10.1186/s12876-019-1095-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 263 |
Lin S, Li Y, Shen L, Zhang R, Yang L, Li M, Li K, Fichna J. The Anti-Inflammatory Effect and Intestinal Barrier Protection of HU210 Differentially Depend on TLR4 Signaling in Dextran Sulfate Sodium-Induced Murine Colitis. Dig Dis Sci 2017;62:372-86. [PMID: 27995407 DOI: 10.1007/s10620-016-4404-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 264 |
Dang XF, Qing-Xi Wang, Yin Z, Sun L, Yang WH. Recurrence of moderate to severe ulcerative colitis after fecal microbiota transplantation treatment and the efficacy of re-FMT: a case series. BMC Gastroenterol 2020;20:401. [PMID: 33243141 DOI: 10.1186/s12876-020-01548-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 265 |
Stiff KM, Cohen PR. Palisaded Granulomatous Dermatitis Associated with Ulcerative Colitis: A Comprehensive Literature Review. Cureus 2017;9:e958. [PMID: 28168136 DOI: 10.7759/cureus.958] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 266 |
Hashimoto K, Saigusa S, Araki T, Tanaka K, Okita Y, Fujikawa H, Kawamura M, Okugawa Y, Toiyama Y, Inoue Y. Correlation of CCL20 expression in rectal mucosa with the development of ulcerative colitis-associated neoplasia. Oncol Lett. 2013;6:1271-1276. [PMID: 24179507 DOI: 10.3892/ol.2013.1528] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 267 |
Danese S, Bonovas S, Peyrin-Biroulet L. Biosimilars in IBD: from theory to practice. Nat Rev Gastroenterol Hepatol. 2017;14:22-31. [PMID: 27729659 DOI: 10.1038/nrgastro.2016.155] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 268 |
Lee SH, Kwon JE, Cho ML. Immunological pathogenesis of inflammatory bowel disease. Intest Res. 2018;16:26-42. [PMID: 29422795 DOI: 10.5217/ir.2018.16.1.26] [Cited by in Crossref: 128] [Cited by in F6Publishing: 123] [Article Influence: 32.0] [Reference Citation Analysis]
|
| 269 |
Alves de Almeida AC, de-Faria FM, Dunder RJ, Manzo LP, Souza-Brito AR, Luiz-Ferreira A. Recent Trends in Pharmacological Activity of Alkaloids in Animal Colitis: Potential Use for Inflammatory Bowel Disease. Evid Based Complement Alternat Med 2017;2017:8528210. [PMID: 28191024 DOI: 10.1155/2017/8528210] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 270 |
Chen K, Wang JM, Yuan R, Yi X, Li L, Gong W, Yang T, Li L, Su S. Tissue-resident dendritic cells and diseases involving dendritic cell malfunction. Int Immunopharmacol 2016;34:1-15. [PMID: 26906720 DOI: 10.1016/j.intimp.2016.02.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 271 |
Sunuwar L, Medini M, Cohen L, Sekler I, Hershfinkel M. The zinc sensing receptor, ZnR/GPR39, triggers metabotropic calcium signalling in colonocytes and regulates occludin recovery in experimental colitis. Philos Trans R Soc Lond B Biol Sci 2016;371:20150420. [PMID: 27377730 DOI: 10.1098/rstb.2015.0420] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 272 |
Fenu E, Lukyanov V, Acs A, Radu X, Stypa S, Fischer A, Marshall JK, Oppe M. Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada. PharmacoEconomics Open. [DOI: 10.1007/s41669-022-00331-9] [Reference Citation Analysis]
|
| 273 |
Damião AOMC, Azevedo MFC, Carlos AS, Wada MY, Silva TVM, Feitosa FC. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review. World J Gastroenterol 2019; 25(9): 1142-1157 [PMID: 30863001 DOI: 10.3748/wjg.v25.i9.1142] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 34] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 274 |
Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2020;8:CD000543. [PMID: 32786164 DOI: 10.1002/14651858.CD000543.pub5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 275 |
Pellegrini C, Fornai M, Colucci R, Benvenuti L, D’Antongiovanni V, Natale G, Fulceri F, Giorgis M, Marini E, Gastaldi S, Bertinaria M, Blandizzi C, Antonioli L. A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation. Front Pharmacol 2018;9:1405. [PMID: 30559669 DOI: 10.3389/fphar.2018.01405] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 276 |
Thapa SD, Hadid H, Usman M, Imam W, Hassan A, Schairer J, Jafri SM, Kaur N. Predictors of Thiopurine Treatment Failure in Biologic-Naïve Ulcerative Colitis Patients. Dig Dis Sci 2016;61:230-7. [PMID: 26511478 DOI: 10.1007/s10620-015-3864-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 277 |
O'Shea CJ, O'Doherty JV, Callanan JJ, Doyle D, Thornton K, Sweeney T. The effect of algal polysaccharides laminarin and fucoidan on colonic pathology, cytokine gene expression and Enterobacteriaceae in a dextran sodium sulfate-challenged porcine model. J Nutr Sci 2016;5:e15. [PMID: 27110358 DOI: 10.1017/jns.2016.4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 278 |
Vikse J, Cacic DL, Carlsen A, Cooper TJ, Grimstad T. A man in his 30s with ulcerative colitis and pancytopenia. Tidsskr Nor Laegeforen 2016;136:1010-4. [PMID: 27325035 DOI: 10.4045/tidsskr.15.0958] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 279 |
Yarani R, Shojaeian A, Palasca O, Doncheva NT, Jensen LJ, Gorodkin J, Pociot F. Differentially Expressed miRNAs in Ulcerative Colitis and Crohn’s Disease. Front Immunol 2022;13:865777. [DOI: 10.3389/fimmu.2022.865777] [Reference Citation Analysis]
|
| 280 |
Heikkilä K, Madsen IE, Nyberg ST, Fransson EI, Ahola K, Alfredsson L, Bjorner JB, Borritz M, Burr H, Dragano N. Job strain and the risk of inflammatory bowel diseases: individual-participant meta-analysis of 95,000 men and women. PLoS One. 2014;9:e88711. [PMID: 24558416 DOI: 10.1371/journal.pone.0088711] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 281 |
Xu H, Luo R, Dong L, Pu X, Chen Q, Ye N, Qi S, Han X, Nie W, Fu C, Hu Y, Zhang J, Gao F. pH/ROS dual-sensitive and chondroitin sulfate wrapped poly (β-amino ester)-SA-PAPE copolymer nanoparticles for macrophage-targeted oral therapy for ulcerative colitis. Nanomedicine 2022;39:102461. [PMID: 34562656 DOI: 10.1016/j.nano.2021.102461] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 282 |
Sun T, Gao GZ, Li RF, Li X, Li DW, Wu SS, Yeo AE, Jin B. Bone marrow-derived mesenchymal stem cell transplantation ameliorates oxidative stress and restores intestinal mucosal permeability in chemically induced colitis in mice. Am J Transl Res 2015;7:891-901. [PMID: 26175850] [Reference Citation Analysis]
|
| 283 |
Bezzio C, Vernero M, Ribaldone DG, Manes G, Saibeni S. Insights into the role of gastrointestinal ultrasound in ulcerative colitis. Therap Adv Gastroenterol 2021;14:17562848211051456. [PMID: 34707688 DOI: 10.1177/17562848211051456] [Reference Citation Analysis]
|
| 284 |
Ahmad H, Verma S, Kumar VL. Effect of roxithromycin on mucosal damage, oxidative stress and pro-inflammatory markers in experimental model of colitis. Inflamm Res 2018;67:147-55. [PMID: 28988395 DOI: 10.1007/s00011-017-1103-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 285 |
Fung QM, Szilagyi A. Carbohydrate Elimination or Adaptation Diet for Symptoms of Intestinal Discomfort in IBD: Rationales for "Gibsons' Conundrum". Int J Inflam 2012;2012:493717. [PMID: 22518336 DOI: 10.1155/2012/493717] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 286 |
Parra-Blanco A, Ruiz A, Alvarez-Lobos M, Amorós A, Gana JC, Ibáñez P, Ono A, Fujii T. Achieving the best bowel preparation for colonoscopy. World J Gastroenterol 2014; 20(47): 17709-17726 [PMID: 25548470 DOI: 10.3748/wjg.v20.i47.17709] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 287 |
Hoy SM. Budesonide MMX(®): a review of its use in patients with mild to moderate ulcerative colitis. Drugs. 2015;75:879-886. [PMID: 25920500 DOI: 10.1007/s40265-015-0396-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 288 |
Fiorino G, Sturniolo GC, Bossa F, Cassinotti A, di Sabatino A, Giuffrida P, Danese S. A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis. Cells 2019;8:E523. [PMID: 31151306 DOI: 10.3390/cells8060523] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 289 |
Yoshino T, Sono M, Yazumi S. Usefulness of sulfasalazine for patients with refractory-ulcerative colits. BMJ Open Gastroenterol 2016;3:e000103. [PMID: 27648296 DOI: 10.1136/bmjgast-2016-000103] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 290 |
Gieseck RL 3rd, Wilson MS, Wynn TA. Type 2 immunity in tissue repair and fibrosis. Nat Rev Immunol. 2018;18:62-76. [PMID: 28853443 DOI: 10.1038/nri.2017.90] [Cited by in Crossref: 305] [Cited by in F6Publishing: 295] [Article Influence: 61.0] [Reference Citation Analysis]
|
| 291 |
Moin AS, Butler PC, Butler AE. Increased Proliferation of the Pancreatic Duct Gland Compartment in Type 1 Diabetes. J Clin Endocrinol Metab 2017;102:200-9. [PMID: 27813705 DOI: 10.1210/jc.2016-3001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 292 |
Meers GK, Bohnenberger H, Reichardt HM, Lühder F, Reichardt SD. Impaired resolution of DSS-induced colitis in mice lacking the glucocorticoid receptor in myeloid cells. PLoS One 2018;13:e0190846. [PMID: 29324769 DOI: 10.1371/journal.pone.0190846] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 293 |
Seishima J, Iida N, Kitamura K, Yutani M, Wang Z, Seki A, Yamashita T, Sakai Y, Honda M, Yamashita T, Kagaya T, Shirota Y, Fujinaga Y, Mizukoshi E, Kaneko S. Gut-derived Enterococcus faecium from ulcerative colitis patients promotes colitis in a genetically susceptible mouse host. Genome Biol 2019;20:252. [PMID: 31767028 DOI: 10.1186/s13059-019-1879-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 294 |
Birchenough G, Schroeder BO, Bäckhed F, Hansson GC. Dietary destabilisation of the balance between the microbiota and the colonic mucus barrier. Gut Microbes 2019;10:246-50. [PMID: 30252606 DOI: 10.1080/19490976.2018.1513765] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 295 |
Brenna Ø, Furnes MW, Drozdov I, van Beelen Granlund A, Flatberg A, Sandvik AK, Zwiggelaar RT, Mårvik R, Nordrum IS, Kidd M, Gustafsson BI. Relevance of TNBS-colitis in rats: a methodological study with endoscopic, histologic and Transcriptomic [corrected] characterization and correlation to IBD. PLoS One 2013;8:e54543. [PMID: 23382912 DOI: 10.1371/journal.pone.0054543] [Cited by in Crossref: 34] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 296 |
Souza DG, Senchenkova EY, Russell J, Granger DN. MyD88 mediates the protective effects of probiotics against the arteriolar thrombosis and leukocyte recruitment associated with experimental colitis. Inflamm Bowel Dis 2015;21:888-900. [PMID: 25738377 DOI: 10.1097/MIB.0000000000000331] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 297 |
Wetzel A, Scholtka B, Schumacher F, Rawel H, Geisendörfer B, Kleuser B. Epigenetic DNA Methylation of EBI3 Modulates Human Interleukin-35 Formation via NFkB Signaling: A Promising Therapeutic Option in Ulcerative Colitis. Int J Mol Sci 2021;22:5329. [PMID: 34069352 DOI: 10.3390/ijms22105329] [Reference Citation Analysis]
|
| 298 |
von Wichert P, Barth P, von Wichert G. Tracheal and bronchial involvement in colitis ulcerosa - a colo-bronchitic syndrome? A case report and some additional considerations. Ger Med Sci 2015;13:Doc03. [PMID: 25834480 DOI: 10.3205/000207] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 299 |
Chen YC, Douville C, Wang C, Niknafs N, Yeo G, Beleva-Guthrie V, Carter H, Stenson PD, Cooper DN, Li B, Mooney S, Karchin R. A probabilistic model to predict clinical phenotypic traits from genome sequencing. PLoS Comput Biol 2014;10:e1003825. [PMID: 25188385 DOI: 10.1371/journal.pcbi.1003825] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 300 |
Lachaine J, Yen L, Beauchemin C, Hodgkins P. Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database. BMC Gastroenterol 2013;13:23. [PMID: 23363459 DOI: 10.1186/1471-230X-13-23] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 301 |
Rydell N, Ekoff H, Hellström PM, Movérare R. Measurement of Serum IgG Anti-Integrin αvβ6 Autoantibodies Is a Promising Tool in the Diagnosis of Ulcerative Colitis. J Clin Med 2022;11:1881. [PMID: 35407486 DOI: 10.3390/jcm11071881] [Reference Citation Analysis]
|
| 302 |
Avni-Biron I, Bar-Gil Shitrit A, Koslowsky B, Levartovsky A, Kopylov U, Weisshof R, Aviv Cohen N, Maharshak N, Hovel D, Israeli E, Naftali T, Goren I, Snir Y, Ollech JE, Banai-Eran H, Broitman Y, Sharar-Fischler T, Dotan I, Yanai H. Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel. Dig Liver Dis 2021:S1590-8658(21)00849-5. [PMID: 34887214 DOI: 10.1016/j.dld.2021.11.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 303 |
Neurath MF. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017;14:269-278. [PMID: 28144028 DOI: 10.1038/nrgastro.2016.208] [Cited by in Crossref: 287] [Cited by in F6Publishing: 250] [Article Influence: 57.4] [Reference Citation Analysis]
|
| 304 |
Zhu F, Ke Y, Luo Y, Wu J, Wu P, Ma F, Liu Y. Effects of Different Treatment of Fecal Microbiota Transplantation Techniques on Treatment of Ulcerative Colitis in Rats. Front Microbiol 2021;12:683234. [PMID: 34335508 DOI: 10.3389/fmicb.2021.683234] [Reference Citation Analysis]
|
| 305 |
Brahmania M, Bernstein CN. Physician global assessments or blood tests do not predict mucosal healing in ulcerative colitis. Can J Gastroenterol Hepatol 2014;28:325-9. [PMID: 24945187 DOI: 10.1155/2014/737349] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 306 |
Bisgaard TH, Allin KH, Keefer L, Ananthakrishnan AN, Jess T. Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35732730 DOI: 10.1038/s41575-022-00634-6] [Reference Citation Analysis]
|
| 307 |
Lira-Junior R, Figueredo CM. Periodontal and inflammatory bowel diseases: Is there evidence of complex pathogenic interactions? World J Gastroenterol 2016; 22(35): 7963-7972 [PMID: 27672291 DOI: 10.3748/wjg.v22.i35.7963] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 43] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 308 |
Chen S, Chen Z, Wang Y, Hao W, Yuan Q, Zhou H, Gao C, Wang Y, Wu X, Wang S. Targeted delivery of Chinese herb pair-based berberine/tannin acid self-assemblies for the treatment of ulcerative colitis. Journal of Advanced Research 2021. [DOI: 10.1016/j.jare.2021.11.017] [Reference Citation Analysis]
|
| 309 |
Ueno N, Sugiyama Y, Kobayashi Y, Murakami Y, Iwama T, Sasaki T, Kunogi T, Takahashi K, Tanaka K, Ando K, Kashima S, Inaba Y, Moriichi K, Tanabe H, Taruishi M, Saitoh Y, Okumura T, Fujiya M. Fecal calprotectin is a useful biomarker for predicting the clinical outcome of granulocyte and monocyte adsorptive apheresis in ulcerative colitis patients: a prospective observation study. BMC Gastroenterol 2021;21:316. [PMID: 34362299 DOI: 10.1186/s12876-021-01889-0] [Reference Citation Analysis]
|
| 310 |
Lian Q, Yan S, Yin Q, Yan C, Zheng W, Gu W, Zhao X, Fan W, Li X, Ma L, Ling Z, Zhang Y, Liu J, Li J, Sun B. TRIM34 attenuates colon inflammation and tumorigenesis by sustaining barrier integrity. Cell Mol Immunol 2021;18:350-62. [PMID: 32094504 DOI: 10.1038/s41423-020-0366-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 311 |
Linssen MD, Hooghiemstra WTR, Jorritsma-Smit A, Allersma DP, Dijkstra G, Nagengast WB. Development and Characterisation of Antibody-Based Optical Imaging Probes for Inflammatory Bowel Disease. Pharmaceuticals (Basel) 2021;14:922. [PMID: 34577622 DOI: 10.3390/ph14090922] [Reference Citation Analysis]
|
| 312 |
Cook MD, Martin SA, Williams C, Whitlock K, Wallig MA, Pence BD, Woods JA. Forced treadmill exercise training exacerbates inflammation and causes mortality while voluntary wheel training is protective in a mouse model of colitis. Brain Behav Immun. 2013;33:46-56. [PMID: 23707215 DOI: 10.1016/j.bbi.2013.05.005] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 8.6] [Reference Citation Analysis]
|
| 313 |
Nishikawa A, Tanaka K, Miyake Y, Nagata C, Furukawa S, Andoh A, Yokoyama T, Yoshimura N, Mori K, Ninomiya T, Yamamoto Y, Takeshita E, Ikeda Y, Saito M, Ohashi K, Imaeda H, Kakimoto K, Higuchi K, Nunoi H, Mizukami Y, Suzuki S, Hiraoka S, Okada H, Kawasaki K, Higashiyama M, Hokari R, Miura H, Miyake T, Kumagi T, Kato H, Hato N, Sayama K, Hiasa Y; Japan Ulcerative Colitis Study Group. Active and passive smoking and risk of ulcerative colitis: A case-control study in Japan. J Gastroenterol Hepatol 2021. [PMID: 34845747 DOI: 10.1111/jgh.15745] [Reference Citation Analysis]
|
| 314 |
Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2020;8:CD000544. [PMID: 32856298 DOI: 10.1002/14651858.CD000544.pub5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 315 |
Ghanadi K, Valizadeh J, Hasanvand A. Epidemiological and clinical aspects of ulcerative colitis in west of Iran: a cross sectional study. Springerplus 2016;5:1588. [PMID: 27652161 DOI: 10.1186/s40064-016-3248-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 316 |
Sugimoto MA, Sousa LP, Pinho V, Perretti M, Teixeira MM. Resolution of Inflammation: What Controls Its Onset? Front Immunol 2016;7:160. [PMID: 27199985 DOI: 10.3389/fimmu.2016.00160] [Cited by in Crossref: 214] [Cited by in F6Publishing: 213] [Article Influence: 35.7] [Reference Citation Analysis]
|
| 317 |
Glas J, Seiderer J, Bues S, Stallhofer J, Fries C, Olszak T, Tsekeri E, Wetzke M, Beigel F, Steib C. IRGM variants and susceptibility to inflammatory bowel disease in the German population. PLoS One. 2013;8:e54338. [PMID: 23365659 DOI: 10.1371/journal.pone.0054338] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 318 |
Hao Y, Nagase K, Hori K, Wang S, Kogure Y, Fukunaga K, Kashiwamura S, Yamamoto S, Nakamura S, Li J, Miwa H, Noguchi K, Dai Y. Xilei san ameliorates experimental colitis in rats by selectively degrading proinflammatory mediators and promoting mucosal repair. Evid Based Complement Alternat Med 2014;2014:569587. [PMID: 25120575 DOI: 10.1155/2014/569587] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 319 |
Genua M, Rutella S, Correale C, Danese S. The triggering receptor expressed on myeloid cells (TREM) in inflammatory bowel disease pathogenesis. J Transl Med 2014;12:293. [PMID: 25347935 DOI: 10.1186/s12967-014-0293-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 320 |
Li C, Wang M, Sui J, Zhou Y, Chen W. Protective mechanisms of Agrimonia pilosa Ledeb in dextran sodium sulfate-induced colitis as determined by a network pharmacology approach. Acta Biochim Biophys Sin (Shanghai) 2021;53:1342-53. [PMID: 34523667 DOI: 10.1093/abbs/gmab116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 321 |
Belarif L, Danger R, Kermarrec L, Nerrière-Daguin V, Pengam S, Durand T, Mary C, Kerdreux E, Gauttier V, Kucik A, Thepenier V, Martin JC, Chang C, Rahman A, Guen NS, Braudeau C, Abidi A, David G, Malard F, Takoudju C, Martinet B, Gérard N, Neveu I, Neunlist M, Coron E, MacDonald TT, Desreumaux P, Mai HL, Le Bas-Bernardet S, Mosnier JF, Merad M, Josien R, Brouard S, Soulillou JP, Blancho G, Bourreille A, Naveilhan P, Vanhove B, Poirier N. IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease. J Clin Invest 2019;129:1910-25. [PMID: 30939120 DOI: 10.1172/JCI121668] [Cited by in Crossref: 33] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 322 |
Dammann K, Khare V, Gasche C. Republished: tracing PAKs from GI inflammation to cancer. Postgrad Med J 2014;90:657-68. [PMID: 25335797 DOI: 10.1136/postgradmedj-2014-306768rep] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 323 |
de Faria FM, Luiz-Ferreira A, Socca EA, de Almeida AC, Dunder RJ, Manzo LP, da Silva MA, Vilegas W, Rozza AL, Pellizzon CH. Effects of Rhizophora mangle on Experimental Colitis Induced by TNBS in Rats. Evid Based Complement Alternat Med. 2012;2012:753971. [PMID: 23056142 DOI: 10.1155/2012/753971] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 324 |
Lau C, Dubinsky M, Melmed G, Vasiliauskas E, Berel D, McGovern D, Ippoliti A, Shih D, Targan S, Fleshner P. The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. Ann Surg. 2015;261:487-496. [PMID: 24950263 DOI: 10.1097/sla.0000000000000757] [Cited by in Crossref: 107] [Cited by in F6Publishing: 36] [Article Influence: 15.3] [Reference Citation Analysis]
|
| 325 |
Lee NS, Pola S, Groessl EJ, Rivera-Nieves J, Ho SB. Opportunities for Improvement in the Care of Patients Hospitalized for Inflammatory Bowel Disease-Related Colitis. Dig Dis Sci 2016;61:1003-12. [PMID: 26860508 DOI: 10.1007/s10620-016-4046-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 326 |
Jeong EM, Son YH, Choi Y, Kim JH, Lee JH, Cho SY, Kim IG. Transglutaminase 2 is dispensable but required for the survival of mice in dextran sulfate sodium-induced colitis. Exp Mol Med 2016;48:e267. [PMID: 27811936 DOI: 10.1038/emm.2016.95] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 327 |
Nelissen LG, Koppen IJN, Follett FR, Boggio-Marzet C, Saps M, Garzon K, Benninga MA. Prevalence of functional gastrointestinal disorders among adolescents in Buenos Aires, Argentina. Rev Gastroenterol Mex (Engl Ed) 2018;83:367-74. [PMID: 29914714 DOI: 10.1016/j.rgmx.2018.02.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 328 |
Schoenmaker SG, Tjon a Ten WE. Ulcerative colitis presenting as acute infectious gastroenteritis with a paralytic ileus. BMJ Case Rep 2012;2012:bcr1120115230. [PMID: 22605860 DOI: 10.1136/bcr.11.2011.5230] [Reference Citation Analysis]
|
| 329 |
France MM, Rio TD, Travers H, Raftery E, Langer R, Traverso G, Schoellhammer CM. Platform for the Delivery of Unformulated RNA In Vivo. J Pharm Sci 2021:S0022-3549(21)00681-X. [PMID: 34906584 DOI: 10.1016/j.xphs.2021.12.008] [Reference Citation Analysis]
|
| 330 |
Cawthorpe D, Davidson M. Temporal comorbidity of mental disorder and ulcerative colitis. Perm J 2015;19:52-7. [PMID: 25663206 DOI: 10.7812/TPP/14-120] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 331 |
Kawalec P, Pilc A. An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis. Arch Med Sci 2016;12:1097-109. [PMID: 27695502 DOI: 10.5114/aoms.2016.58682] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 332 |
Schneditz G, Elias JE, Pagano E, Zaeem Cader M, Saveljeva S, Long K, Mukhopadhyay S, Arasteh M, Lawley TD, Dougan G, Bassett A, Karlsen TH, Kaser A, Kaneider NC. GPR35 promotes glycolysis, proliferation, and oncogenic signaling by engaging with the sodium potassium pump. Sci Signal 2019;12:eaau9048. [PMID: 30600262 DOI: 10.1126/scisignal.aau9048] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 333 |
Schneider M, Efferth T, Abdel-Aziz H. Anti-inflammatory Effects of Herbal Preparations STW5 and STW5-II in Cytokine-Challenged Normal Human Colon Cells. Front Pharmacol. 2016;7:393. [PMID: 27833553 DOI: 10.3389/fphar.2016.00393] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 334 |
Van der Goten J, Vanhove W, Lemaire K, Van Lommel L, Machiels K, Wollants WJ, De Preter V, De Hertogh G, Ferrante M, Van Assche G. Integrated miRNA and mRNA expression profiling in inflamed colon of patients with ulcerative colitis. PLoS One. 2014;9:e116117. [PMID: 25546151 DOI: 10.1371/journal.pone.0116117] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 335 |
de Aguiar CF, Castoldi A, Andrade-Oliveira V, Ignacio A, da Cunha FF, Felizardo RJF, Bassi ÊJ, Câmara NOS, de Almeida DC. Mesenchymal stromal cells modulate gut inflammation in experimental colitis. Inflammopharmacology 2018;26:251-60. [PMID: 29063489 DOI: 10.1007/s10787-017-0404-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 336 |
Stylianou E. Epigenetics: the fine-tuner in inflammatory bowel disease? Curr Opin Gastroenterol. 2013;29:370-377. [PMID: 23743674 DOI: 10.1097/mog.0b013e328360bd12] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 337 |
Lian L, Obusez E, Remer EM, Monga M, Shen B. Clinical Implication of Enlarged Prostate in Patients with the Ileal Pouch-anal Anastomosis for Inflammatory Bowel Disease. Gastroenterology Res 2018;11:5-10. [PMID: 29511399 DOI: 10.14740/gr975e] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 338 |
Vaughn BP, Moss AC. Novel treatment options for ulcerative colitis. Clin Investig (Lond) 2013;3:1057-69. [PMID: 24533177 DOI: 10.4155/cli.13.97] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 339 |
Boland BS, Sandborn WJ, Chang JT. Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin North Am. 2014;43:603-617. [PMID: 25110261 DOI: 10.1016/j.gtc.2014.05.011] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 340 |
Jefremow A, Neurath MF. All are Equal, Some are More Equal: Targeting IL 12 and 23 in IBD - A Clinical Perspective. Immunotargets Ther 2020;9:289-97. [PMID: 33274187 DOI: 10.2147/ITT.S282466] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 341 |
Qian K, Yuan L, Wang S, Kuang Y, Jin Q, Long D, Jiang Y, Zhao H, Liu K, Yao H. Inhibitor of apoptosis-stimulating p53 protein protects against inflammatory bowel disease in mice models by inhibiting the nuclear factor kappa B signaling. Clin Exp Immunol 2021;205:246-56. [PMID: 33942299 DOI: 10.1111/cei.13613] [Reference Citation Analysis]
|
| 342 |
Kwon OC, Han K, Chun J, Kim R, Hong SW, Kim JH, Youn YH, Park H, Park MC; Gastroenterology, Neurology and Rheumatology National Data Science Research (GUARANTEE) Group. Effects of immune-mediated inflammatory diseases on cardiovascular diseases in patients with type 2 diabetes: a nationwide population-based study. Sci Rep 2022;12:11548. [PMID: 35798796 DOI: 10.1038/s41598-022-15436-8] [Reference Citation Analysis]
|
| 343 |
Lam WC, Zhao C, Ma WJ, Yao L. The Clinical and Steroid-Free Remission of Fecal Microbiota Transplantation to Patients with Ulcerative Colitis: A Meta-Analysis. Gastroenterol Res Pract 2019;2019:1287493. [PMID: 31178906 DOI: 10.1155/2019/1287493] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 344 |
Vyas SP, Goswami R. A Decade of Th9 Cells: Role of Th9 Cells in Inflammatory Bowel Disease. Front Immunol 2018;9:1139. [PMID: 29881387 DOI: 10.3389/fimmu.2018.01139] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 345 |
Feng BS, Ma N, Zhang YY, Gao H, Zhang C, Li G, Liu Z, Feng Y, Yu HQ, Xiao L, Liu ZG, Yang PC. Survivin Impairs the Apoptotic Machinery in CD4+ T Cells of Patients with Ulcerative Colitis. J Innate Immun 2020;12:226-34. [PMID: 31330513 DOI: 10.1159/000500546] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 346 |
Sarvestani SK, Signs SA, Lefebvre V, Mack S, Ni Y, Morton A, Chan ER, Li X, Fox P, Ting A, Kalady MF, Cruise M, Ashburn J, Stiene J, Lai W, Liska D, Xiang S, Huang EH. Cancer-predicting transcriptomic and epigenetic signatures revealed for ulcerative colitis in patient-derived epithelial organoids. Oncotarget. 2018;9:28717-28730. [PMID: 29983891 DOI: 10.18632/oncotarget.25617] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 347 |
Hayashi R, Ueno Y, Tanaka S, Sagami S, Nagai K, Shigemoto N, Uegami S, Shimizu W, Watadani Y, Ohge H, Chayama K. Two Cases of Severe Ulcerative Colitis with Colonic Dilatation Resolved with Tacrolimus Therapy. Case Rep Gastroenterol 2015;9:272-7. [PMID: 26351416 DOI: 10.1159/000438784] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 348 |
Kuna AT. Serological markers of inflammatory bowel disease. Biochem Med (Zagreb). 2013;23:28-42. [PMID: 23457764 DOI: 10.11613/BM.2013.006] [Cited by in Crossref: 46] [Cited by in F6Publishing: 22] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 349 |
Hiyama K, Terashima H, Nakano Y, Kamiga M, Harada K, Horiguchi H, Mamiya T. Primary rectal diffuse large B-cell lymphoma associated with ulcerative colitis: a case report. Clin Case Rep 2015;3:150-5. [PMID: 25838903 DOI: 10.1002/ccr3.185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 350 |
Vaizey CJ, Gibson PR, Black CM, Nicholls RJ, Weston AR, Gaya DR, Sebastian S, Shaw I, Lewis S, Bloom S, Gordon JN, Beale A, Arnott I, Campbell S, Fan T. Disease status, patient quality of life and healthcare resource use for ulcerative colitis in the UK: an observational study. Frontline Gastroenterol 2014;5:183-9. [PMID: 28839768 DOI: 10.1136/flgastro-2013-100409] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 351 |
Kwon SC, Won KJ, Jung SH, Lee KP, Lee DY, Park ES, Kim B, Cheon GJ, Han KH. Proteomic analysis of colonic mucosal tissue from tuberculous and ulcerative colitis patients. Korean J Physiol Pharmacol 2012;16:193-8. [PMID: 22802701 DOI: 10.4196/kjpp.2012.16.3.193] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 352 |
Zhang Y, Desai A, Yang SY, Bae KB, Antczak MI, Fink SP, Tiwari S, Willis JE, Williams NS, Dawson DM, Wald D, Chen WD, Wang Z, Kasturi L, Larusch GA, He L, Cominelli F, Di Martino L, Djuric Z, Milne GL, Chance M, Sanabria J, Dealwis C, Mikkola D, Naidoo J, Wei S, Tai HH, Gerson SL, Ready JM, Posner B, Willson JK, Markowitz SD. TISSUE REGENERATION. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration. Science 2015;348:aaa2340. [PMID: 26068857 DOI: 10.1126/science.aaa2340] [Cited by in Crossref: 140] [Cited by in F6Publishing: 134] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 353 |
Kuwahara E, Murakami Y, Nakamura T, Inoue N, Nagahori M, Matsui T, Watanabe M, Suzuki Y, Nishiwaki Y. Factors associated with exacerbation of newly diagnosed mild ulcerative colitis based on a nationwide registry in Japan. J Gastroenterol 2017;52:185-93. [PMID: 27075755 DOI: 10.1007/s00535-016-1209-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 354 |
Actis GC, Pellicano R, Rosina F. Inflammatory bowel disease: Traditional knowledge holds the seeds for the future. World J Gastrointest Pharmacol Ther 2015; 6(2): 10-16 [PMID: 25949845 DOI: 10.4292/wjgpt.v6.i2.10] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 355 |
Danese S, Hart A, Dignass A, Fiorino G, Louis E, Bonovas S, D'Haens G, Dotan I, Rogler G, Paridaens K, Peyrin-Biroulet L. A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX®) for active, mild-to-moderate ulcerative colitis. United European Gastroenterol J 2019;7:1171-82. [PMID: 31700630 DOI: 10.1177/2050640619864848] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 356 |
Schoehl J, Mechie NC, Schwoerer H, Moerer O, Quintel M, Buck C, Ellenrieder V, Neesse A, Amanzada A. Severe Acute Respiratory Distress Syndrome during Infliximab Therapy in a Patient with Crohn Disease. Case Rep Gastroenterol 2016;10:574-80. [PMID: 27920644 DOI: 10.1159/000450676] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 357 |
Lin L, Liu X, Wang D, Zheng C. Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis. Medicine (Baltimore). 2015;94:e556. [PMID: 25761174 DOI: 10.1097/md.0000000000000556] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 358 |
Yang S, Yang S, Kwon Jo Y, Kim S, Jung Chang M, Choi J, Hee Cheon J, Yu YM. Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis. Ther Adv Chronic Dis 2021;12:20406223211041927. [PMID: 34729142 DOI: 10.1177/20406223211041927] [Reference Citation Analysis]
|
| 359 |
Hu W, Fang T, Chen X. Identification of Differentially Expressed Genes and miRNAs for Ulcerative Colitis Using Bioinformatics Analysis. Front Genet 2022;13:914384. [DOI: 10.3389/fgene.2022.914384] [Reference Citation Analysis]
|
| 360 |
Toiyama Y, Okugawa Y, Kondo S, Okita Y, Araki T, Kusunoki K, Uchino M, Ikeuchi H, Hirota S, Mitsui A, Takehana K, Umezawa T, Kusunoki M. Comprehensive analysis identifying aberrant DNA methylation in rectal mucosa from ulcerative colitis patients with neoplasia. Oncotarget 2018;9:33149-59. [PMID: 30237858 DOI: 10.18632/oncotarget.26032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 361 |
Uygun A, Ozturk K, Demirci H, Oger C, Avci IY, Turker T, Gulsen M. Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis. Medicine (Baltimore) 2017;96:e6479. [PMID: 28422836 DOI: 10.1097/MD.0000000000006479] [Cited by in Crossref: 34] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 362 |
Li C, Fan YF, Liu H, Zhang QD. Therapeutic effect of Shaohuang Anchang decoction on active ulcerative colitis and serum levels of TNF-α, IL-17 and IL-21. Shijie Huaren Xiaohua Zazhi 2013; 21(32): 3580-3584 [DOI: 10.11569/wcjd.v21.i32.3580] [Reference Citation Analysis]
|
| 363 |
Kim E, Kim Y, Lee J, Shin J, Seok PR, Kim Y, Yoo S. Leucrose, a natural sucrose isomer, suppresses dextran sulfate sodium (DSS)-induced colitis in mice by regulating macrophage polarization via JAK1/STAT6 signaling. Journal of Functional Foods 2020;74:104156. [DOI: 10.1016/j.jff.2020.104156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 364 |
Shen Y, Ma J, Yan R, Ling H, Li X, Yang W, Gao J, Huang C, Bu Y, Cao Y, He Y, Wan L, Zu X, Liu J, Huang MC, Stenson WF, Liao DF, Cao D. Impaired self-renewal and increased colitis and dysplastic lesions in colonic mucosa of AKR1B8-deficient mice. Clin Cancer Res 2015;21:1466-76. [PMID: 25538260 DOI: 10.1158/1078-0432.CCR-14-2072] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 365 |
Yu L, Yang F, Zhang F, Guo D, Li L, Wang X, Liang T, Wang J, Cai Z, Jin H. CD69 enhances immunosuppressive function of regulatory T-cells and attenuates colitis by prompting IL-10 production. Cell Death Dis 2018;9:905. [PMID: 30185773 DOI: 10.1038/s41419-018-0927-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 366 |
Calderón-Torres CM, Sarabia-Curz L, Ledesma-Soto Y, Murguía-Romero M, Terrazas LI. Denitrase activity of Debaryomyces hansenii reduces the oxidized compound 3-nitrotyrosine in mice liver with colitis. Exp Ther Med 2019;17:3748-54. [PMID: 31007730 DOI: 10.3892/etm.2019.7395] [Reference Citation Analysis]
|
| 367 |
O'Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 2013;72 Suppl 2:ii111-5. [PMID: 23532440 DOI: 10.1136/annrheumdis-2012-202576] [Cited by in Crossref: 222] [Cited by in F6Publishing: 208] [Article Influence: 24.7] [Reference Citation Analysis]
|
| 368 |
Sakellakis M, Makatsoris T, Gkermpesi M, Peroukidis S, Kalofonos H. Ulcerative colitis six years after colon cancer: only a coincidence? Int Med Case Rep J 2014;7:85-8. [PMID: 24855393 DOI: 10.2147/IMCRJ.S61950] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 369 |
Stankovic B, Kotur N, Nikcevic G, Gasic V, Zukic B, Pavlovic S. Machine Learning Modeling from Omics Data as Prospective Tool for Improvement of Inflammatory Bowel Disease Diagnosis and Clinical Classifications. Genes (Basel) 2021;12:1438. [PMID: 34573420 DOI: 10.3390/genes12091438] [Reference Citation Analysis]
|
| 370 |
Lu JJ, Maimaiti M, Liu H, Liu WD, Hui WJ, Huang XL, Gao F. Potential Biomarkers Associated with Differential Manifestations of Ulcerative Colitis (UC) in Uyghur and Han Population in China. J Inflamm Res 2021;14:7431-41. [PMID: 35002277 DOI: 10.2147/JIR.S335293] [Reference Citation Analysis]
|
| 371 |
Wiese DM, Horst SN, Brown CT, Allaman MM, Hodges ME, Slaughter JC, Druce JP, Beaulieu DB, Schwartz DA, Wilson KT, Coburn LA. Serum Fatty Acids Are Correlated with Inflammatory Cytokines in Ulcerative Colitis. PLoS One 2016;11:e0156387. [PMID: 27227540 DOI: 10.1371/journal.pone.0156387] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 372 |
Li Q, Qu X, Pang X, Song Y, Chen L, Xiao Q, Sun L, Wang X, Zhang H, Qi D, Wang Z. Berberine Protects Mice Against Dextran Sulfate Sodium-Induced Colitis by Activating mTORC1 Pathway. Front Pharmacol 2019;10:786. [PMID: 31354497 DOI: 10.3389/fphar.2019.00786] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 373 |
Volpato E, Bosio C, Previtali E, Leone S, Armuzzi A, Pagnini F, Graffigna G. The evolution of IBD perceived engagement and care needs across the life-cycle: a scoping review. BMC Gastroenterol 2021;21:293. [PMID: 34261434 DOI: 10.1186/s12876-021-01850-1] [Reference Citation Analysis]
|
| 374 |
Francescone R, Hou V, Grivennikov SI. Cytokines, IBD, and colitis-associated cancer. Inflamm Bowel Dis. 2015;21:409-418. [PMID: 25563695 DOI: 10.1097/mib.0000000000000236] [Cited by in Crossref: 163] [Cited by in F6Publishing: 104] [Article Influence: 23.3] [Reference Citation Analysis]
|
| 375 |
Földes A, Kádár K, Kerémi B, Zsembery Á, Gyires K, S Zádori Z, Varga G. Mesenchymal Stem Cells of Dental Origin-Their Potential for Antiinflammatory and Regenerative Actions in Brain and Gut Damage. Curr Neuropharmacol 2016;14:914-34. [PMID: 26791480 DOI: 10.2174/1570159x14666160121115210] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 376 |
Sarvestani SK, Signs S, Hu B, Yeu Y, Feng H, Ni Y, Hill DR, Fisher RC, Ferrandon S, DeHaan RK, Stiene J, Cruise M, Hwang TH, Shen X, Spence JR, Huang EH. Induced organoids derived from patients with ulcerative colitis recapitulate colitic reactivity. Nat Commun 2021;12:262. [PMID: 33431859 DOI: 10.1038/s41467-020-20351-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 377 |
Bertani L, Baglietto L, Antonioli L, Fornai M, Tapete G, Albano E, Ceccarelli L, Mumolo MG, Pellegrini C, Lucenteforte E, de Bortoli N, Bellini M, Marchi S, Blandizzi C, Costa F. Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. Br J Clin Pharmacol 2020;86:1296-305. [PMID: 32027388 DOI: 10.1111/bcp.14235] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 378 |
Santhosh S, Bhattacharya A, Rana SS, Bhasin DK, Gupta R, Mittal BR. Noninvasive evaluation of active pan-ulcerative colitis with multiple strictures using Fluorine-18-Fluorodeoxyglucose positron emission tomography/computed tomography. Indian J Nucl Med 2016;31:65-6. [PMID: 26917901 DOI: 10.4103/0972-3919.172367] [Reference Citation Analysis]
|
| 379 |
. Stellungnahme der DGVS zur Nutzenbewertung des GBA zum Wirkstoff Filgotinib (Anwendungsgebiet: Colitis Ulcerosa, vorbehandelte Patient*innen). Z Gastroenterol 2022;60:1047-50. [DOI: 10.1055/a-1851-7777] [Reference Citation Analysis]
|
| 380 |
Ren PW, Yang WJ, Wang DD, Shan JY, Kang DY, Hong Q, Wen S, Zhang RW. Kangfuxinye Enema Combined with Mesalamine for Ulcerative Colitis: A Systematic Review and GRADE Approach. Evid Based Complement Alternat Med 2017;2017:6019530. [PMID: 28848616 DOI: 10.1155/2017/6019530] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 381 |
Sugimoto S, Naganuma M, Kanai T. Indole compounds may be promising medicines for ulcerative colitis. J Gastroenterol 2016;51:853-61. [DOI: 10.1007/s00535-016-1220-2] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 382 |
Jin X, Chen YP, Chen SH, Xiang Z. Association between Helicobacter Pylori infection and ulcerative colitis--a case control study from China. Int J Med Sci. 2013;10:1479-1484. [PMID: 24046521 DOI: 10.7150/ijms.6934] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 383 |
Zhang T, Cui B, Li P, He Z, Long C, Wei L, Peng Z, Ji G, Zhang F. Short-Term Surveillance of Cytokines and C-Reactive Protein Cannot Predict Efficacy of Fecal Microbiota Transplantation for Ulcerative Colitis. PLoS One 2016;11:e0158227. [PMID: 27347881 DOI: 10.1371/journal.pone.0158227] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 384 |
Almeida Junior LD, Quaglio AEV, de Almeida Costa CAR, Di Stasi LC. Intestinal anti-inflammatory activity of Ground Cherry (Physalis angulata L.) standardized CO2 phytopharmaceutical preparation. World J Gastroenterol 2017; 23(24): 4369-4380 [PMID: 28706419 DOI: 10.3748/wjg.v23.i24.4369] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 385 |
Baumgart DC, le Claire M. The Expenditures for Academic Inpatient Care of Inflammatory Bowel Disease Patients Are Almost Double Compared with Average Academic Gastroenterology and Hepatology Cases and Not Fully Recovered by Diagnosis-Related Group (DRG) Proceeds. PLoS One 2016;11:e0147364. [PMID: 26784027 DOI: 10.1371/journal.pone.0147364] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 386 |
Morís G. Inflammatory bowel disease: An increased risk factor for neurologic complications. World J Gastroenterol 2014; 20(5): 1228-1237 [PMID: 24574797 DOI: 10.3748/wjg.v20.i5.1228] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 50] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 387 |
Ashton JJ, Mossotto E, Ennis S, Beattie RM. Personalising medicine in inflammatory bowel disease-current and future perspectives. Transl Pediatr 2019;8:56-69. [PMID: 30881899 DOI: 10.21037/tp.2018.12.03] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 388 |
Sohail M, Mudassir, Minhas MU, Khan S, Hussain Z, de Matas M, Shah SA, Khan S, Kousar M, Ullah K. Natural and synthetic polymer-based smart biomaterials for management of ulcerative colitis: a review of recent developments and future prospects. Drug Deliv Transl Res 2019;9:595-614. [PMID: 29611113 DOI: 10.1007/s13346-018-0512-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 389 |
Ciorba MA. A gastroenterologist’s guide to probiotics. Clin Gastroenterol Hepatol. 2012;10:960-968. [PMID: 22504002 DOI: 10.1016/j.cgh.2012.03.024] [Cited by in Crossref: 93] [Cited by in F6Publishing: 68] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 390 |
Maconi G, Furfaro F, Sciurti R, Bezzio C, Ardizzone S, de Franchis R. Glucose intolerance and diabetes mellitus in ulcerative colitis: Pathogenetic and therapeutic implications. World J Gastroenterol 2014; 20(13): 3507-3515 [PMID: 24707133 DOI: 10.3748/wjg.v20.i13.3507] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 391 |
Lv C, Zhao X, Gu H, Huang L, Zhou S, Zhi F. Involvement of Activated Cdc42 Kinase1 in Colitis and Colorectal Neoplasms. Med Sci Monit 2016;22:4794-802. [PMID: 27926694 DOI: 10.12659/msm.902274] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 392 |
Yarlas A, Maher SM, Bayliss MS, Lovley A, Cappelleri JC, DiBonaventura MD. Psychometric validation of the work productivity and activity impairment questionnaire in ulcerative colitis: results from a systematic literature review. J Patient Rep Outcomes. 2018;2:62. [PMID: 30547275 DOI: 10.1186/s41687-018-0088-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 393 |
Halpin SJ, Hamlin PJ, Greer DP, Warren L, Ford AC. Efficacy of infliximab in acute severe ulcerative colitis: A single-centre experience. World J Gastroenterol 2013; 19(7): 1091-1097 [PMID: 23467174 DOI: 10.3748/wjg.v19.i7.1091] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 394 |
Gokli A, Dillman JR, Humphries PD, Ključevšek D, Mentzel HJ, Rubesova E, Takahashi MS, Anupindi SA. Contrast-enhanced ultrasound of the pediatric bowel. Pediatr Radiol 2021. [PMID: 33978797 DOI: 10.1007/s00247-020-04868-x] [Reference Citation Analysis]
|
| 395 |
Shiraki M, Yamamoto T. Steroid-sparing strategies in the management of ulcerative colitis: Efficacy of leukocytapheresis. World J Gastroenterol 2012; 18(41): 5833-5838 [PMID: 23139598 DOI: 10.3748/wjg.v18.i41.5833] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 396 |
Sun YX, Yang GY, Karamacoska D, Wang X, Li YX, Hou WB, Zheng YY, Liu JP, Liu ZL. Chinese Patent Medicine as Adjuvant for Mild-to-Moderate Active Ulcerative Colitis: A Network Meta-Analysis of Randomized Controlled Trials. Evid Based Complement Alternat Med 2021;2021:1075886. [PMID: 34484384 DOI: 10.1155/2021/1075886] [Reference Citation Analysis]
|
| 397 |
Gabbani T, Manetti N, Bagnoli S, Annese V. Beclomethasone dipropionate for the treatment of ulcerative colitis. Expert Opinion on Orphan Drugs 2014;3:87-96. [DOI: 10.1517/21678707.2014.968125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 398 |
Ruder B, Atreya R, Becker C. Tumour Necrosis Factor Alpha in Intestinal Homeostasis and Gut Related Diseases. Int J Mol Sci 2019;20:E1887. [PMID: 30995806 DOI: 10.3390/ijms20081887] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 12.3] [Reference Citation Analysis]
|
| 399 |
Zhao X, Li N, Ren Y, Ma T, Wang C, Wang J, You S. Efficacy and Safety of Beclomethasone Dipropionate versus 5-Aminosalicylic Acid in the Treatment of Ulcerative Colitis: A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0160500. [PMID: 27501314 DOI: 10.1371/journal.pone.0160500] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 400 |
Shin SY, Kim S, Choi JW, Kang S, Kim TO, Seo GS, Cha JM, Chun J, Jung Y, Im JP, Bang KB, Choi CH, Park S, Park DI. The Common and Unique Pattern of Microbiome Profiles among Saliva, Tissue, and Stool Samples in Patients with Crohn’s Disease. Microorganisms 2022;10:1467. [DOI: 10.3390/microorganisms10071467] [Reference Citation Analysis]
|
| 401 |
Bouguen G, Langlois A, Djouina M, Branche J, Koriche D, Dewaeles E, Mongy A, Auwerx J, Colombel JF, Desreumaux P, Dubuquoy L, Bertin B. Intestinal steroidogenesis controls PPARγ expression in the colon and is impaired during ulcerative colitis. Gut 2015;64:901-10. [PMID: 25053717 DOI: 10.1136/gutjnl-2014-307618] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 402 |
Novak EA, Mollen KP. Mitochondrial dysfunction in inflammatory bowel disease. Front Cell Dev Biol. 2015;3:62. [PMID: 26484345 DOI: 10.3389/fcell.2015.00062] [Cited by in Crossref: 98] [Cited by in F6Publishing: 98] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 403 |
Takahashi K, Nakagawasai O, Nemoto W, Odaira T, Sakuma W, Onogi H, Nishijima H, Furihata R, Nemoto Y, Iwasa H, Tan-No K, Tadano T. Effect of Enterococcus faecalis 2001 on colitis and depressive-like behavior in dextran sulfate sodium-treated mice: involvement of the brain-gut axis. J Neuroinflammation 2019;16:201. [PMID: 31672153 DOI: 10.1186/s12974-019-1580-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 404 |
Zundler S, Neurath MF. Integrating Immunologic Signaling Networks: The JAK/STAT Pathway in Colitis and Colitis-Associated Cancer. Vaccines (Basel). 2016;4:5. [PMID: 26938566 DOI: 10.3390/vaccines4010005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 405 |
Sundblad V, Quintar AA, Morosi LG, Niveloni SI, Cabanne A, Smecuol E, Mauriño E, Mariño KV, Bai JC, Maldonado CA, Rabinovich GA. Galectins in Intestinal Inflammation: Galectin-1 Expression Delineates Response to Treatment in Celiac Disease Patients. Front Immunol 2018;9:379. [PMID: 29545799 DOI: 10.3389/fimmu.2018.00379] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 406 |
Long MD, Smith TW, Dibonaventura M, Gruben D, Bargo D, Salese L, Quirk D. Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States. Inflamm Bowel Dis 2020;26:941-8. [PMID: 31560046 DOI: 10.1093/ibd/izz204] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 407 |
Sutton RT, Zai Ane OR, Goebel R, Baumgart DC. Artificial intelligence enabled automated diagnosis and grading of ulcerative colitis endoscopy images. Sci Rep 2022;12:2748. [PMID: 35177717 DOI: 10.1038/s41598-022-06726-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 408 |
Lin CY, Tseng KS, Liu JM, Chuang HC, Lien CH, Chen YC, Lai CY, Yu CP, Hsu RJ. Increased Risk of Ulcerative Colitis in Patients with Periodontal Disease: A Nationwide Population-Based Cohort Study. Int J Environ Res Public Health. 2018;15. [PMID: 30469385 DOI: 10.3390/ijerph15112602] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 409 |
Zhang J, Wang W, Zhu S, Chen Y. Increased SERPINA3 Level Is Associated with Ulcerative Colitis. Diagnostics (Basel) 2021;11:2371. [PMID: 34943607 DOI: 10.3390/diagnostics11122371] [Reference Citation Analysis]
|
| 410 |
Pyo JY, Park JS, Song CH, Lee SW, Park YB, Lee SK. Takayasu arteritis associated with ulcerative colitis and optic neuritis: first case in Korea. Korean J Intern Med 2013;28:491-6. [PMID: 23864809 DOI: 10.3904/kjim.2013.28.4.491] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 411 |
Mavroudis G, Simrén M, Öhman L, Strid H. Health-related quality of life in patients with long-standing ulcerative colitis in remission. Therap Adv Gastroenterol 2022;15:175628482110624. [DOI: 10.1177/17562848211062406] [Reference Citation Analysis]
|
| 412 |
Thomas S, Mercado JM, DuHadaway J, DiGuilio K, Mullin JM, Prendergast GC. Novel Colitis Immunotherapy Targets Bin1 and Improves Colon Cell Barrier Function. Dig Dis Sci 2016;61:423-32. [PMID: 26195312 DOI: 10.1007/s10620-015-3804-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 413 |
Ma X, Hu Y, Li X, Zheng X, Wang Y, Zhang J, Fu C, Geng F. Periplaneta americana Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Rats by Keap1/Nrf-2 Activation, Intestinal Barrier Function, and Gut Microbiota Regulation. Front Pharmacol. 2018;9:944. [PMID: 30186174 DOI: 10.3389/fphar.2018.00944] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 414 |
Travis SP, Danese S, Kupcinskas L, Alexeeva O, D'Haens G, Gibson PR, Moro L, Jones R, Ballard ED, Masure J, Rossini M, Sandborn WJ. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014;63:433-41. [PMID: 23436336 DOI: 10.1136/gutjnl-2012-304258] [Cited by in Crossref: 167] [Cited by in F6Publishing: 141] [Article Influence: 20.9] [Reference Citation Analysis]
|
| 415 |
Bai X, Gou X, Cai P, Xu C, Cao L, Zhao Z, Huang M, Jin J. Sesamin Enhances Nrf2-Mediated Protective Defense against Oxidative Stress and Inflammation in Colitis via AKT and ERK Activation. Oxid Med Cell Longev 2019;2019:2432416. [PMID: 31534619 DOI: 10.1155/2019/2432416] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 416 |
Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14:329-342. [PMID: 24751956 DOI: 10.1038/nri3661] [Cited by in Crossref: 1129] [Cited by in F6Publishing: 1090] [Article Influence: 141.1] [Reference Citation Analysis]
|
| 417 |
Wu M, Lin Z, Ma S, Chen T, Jiang R, Wong WH. Simultaneous inference of phenotype-associated genes and relevant tissues from GWAS data via Bayesian integration of multiple tissue-specific gene networks. J Mol Cell Biol 2017;9:436-52. [PMID: 29300920 DOI: 10.1093/jmcb/mjx059] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 418 |
Cao Y, Zhang B, Wu Y, Wang Q, Wang J, Shen F. The Value of Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract 2018;2018:5480961. [PMID: 29849592 DOI: 10.1155/2018/5480961] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 419 |
Fuchs F, Schillinger D, Atreya R, Hirschmann S, Fischer S, Neufert C, Atreya I, Neurath MF, Zundler S. Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles. Front Immunol 2017;8:764. [PMID: 28717358 DOI: 10.3389/fimmu.2017.00764] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 420 |
Monstad IL, Solberg IC, Cvancarova M, Hovde O, Henriksen M, Huppertz-Hauss G, Gunther E, Moum BA, Stray N, Vatn M, Hoie O, Jahnsen J. Outcome of Ulcerative Colitis 20 Years after Diagnosis in a Prospective Population-based Inception Cohort from South-Eastern Norway, the IBSEN Study. J Crohns Colitis 2021;15:969-79. [PMID: 33367569 DOI: 10.1093/ecco-jcc/jjaa232] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 421 |
Akazawa Y, Morisaki T, Fukuda H, Norimatsu K, Shiota J, Hashiguchi K, Tabuchi M, Kitayama M, Matsushima K, Yamaguchi N, Kondo H, Fujita F, Takeshita H, Nakao K, Takeshima F. Significance of serum palmitoleic acid levels in inflammatory bowel disease. Sci Rep 2021;11:16260. [PMID: 34376800 DOI: 10.1038/s41598-021-95923-6] [Reference Citation Analysis]
|
| 422 |
Nalleweg N, Chiriac MT, Podstawa E, Lehmann C, Rau TT, Atreya R, Krauss E, Hundorfean G, Fichtner-Feigl S, Hartmann A, Becker C, Mudter J. IL-9 and its receptor are predominantly involved in the pathogenesis of UC. Gut 2015;64:743-55. [PMID: 24957265 DOI: 10.1136/gutjnl-2013-305947] [Cited by in Crossref: 109] [Cited by in F6Publishing: 108] [Article Influence: 15.6] [Reference Citation Analysis]
|
| 423 |
Spadaccini M, D'Alessio S, Peyrin-Biroulet L, Danese S. PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue. Int J Mol Sci. 2017;18. [PMID: 28617319 DOI: 10.3390/ijms18061276] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 424 |
Trindade IA, Ferreira C, Pinto-Gouveia J. Ulcerative Colitis Symptomatology and Depression: The Exacerbator Role of Maladaptive Psychological Processes. Dig Dis Sci 2015;60:3756-63. [PMID: 26141631 DOI: 10.1007/s10620-015-3786-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
|
